Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > Free Zone > All Trading - Technical >


RSS Feed
      Hide Sticky   Hide Intro
Moderator: kiy Assistants:
Search This Board: 
Last Post: 7/26/2017 10:09:52 PM - Followers: 5 - Board type: Free - Posts Today: 0

Speculation Stocks ...
There isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and solid risk management are banking ridiculous coin on a regular basis. Roberto Pedone...
They took a company with essentially no business operations and little revenue and deceived the market and their clients into believing it was worth hundreds of millions of dollars through a dizzying round of unauthorized trades and deceptive promotions. In the end, the deceived investors were left holding the empty bag,”

Some RULES for this I-Hub Board...........

This board will be used for analysis of charts ranging in different time periods to determine signals for trading of various instruments=individual stocks, etf's and options. Please direct your comments towards technical indicators that everyone can see on a price chart:  we are talking about signals and technical indicators here, not opinions or predictions or forecasts of  when the next grand slam will be... share technical signals and charts with the group and if you have an active position......  Rather than being opinionated and letting your subjective bias determine which side of the market to be on,  try to maintain objectivity based on technical analysis. 
 One of the key items to remember as investors/traders is that the market doesn't always reflect reality. Oftentimes it reflects belief. And belief can prove to be a delusion. 

"A belief held without objective examples that everyone can see is a delusion."
“Opinion is that exercise of the human will which 'lets' us make a decision without objective information and objective examples.” And is obviously ....not the best choice that promotes a healthy process.
“Discussion is an exchange of knowledge; an argument an exchange of ignorance.”
Understand the above and you will understand the phrase..."Self will run riot" and you can expect  the results  of this riot will be destructive for yourself first and then for others.
Dysfunctional attitudes and behaviors = "self will run riot" it is not a process that builds "character".  It is not common decency, nor  any form of can only be destructive. 

                                                  It is no disgrace to be wrong... disgrace happens when you choose to stay wrong...
                                                                                                              Anticipation vs. Rewards: Is it in the Stock or in the Brain?

Life's Lessons
Lesson #1 – The cover up is often worse than the original problem. Don’t expect them to admit it.
Strategy #1: “The best way to expose a liar is to just let them keep talking”.
Strategy #2: “Make sure to give the guilty party enough rope to hang themselves”.
Building character is a project you never complete.
We form our character in defining moments because we commit to irreversible courses of action that shape our personal and professional identities. We reveal something new about us to ourselves and others because defining moments uncover something that had been hidden or crystallize something that had been only partially known. And we test ourselves because we discover whether we will live up to our personal ideals or only pay them lip service.

If you feel you must GAMBLE and encourage gambling from the 5 minute or lower time frames you will be asked to take  your message to the "gamblers board"...If you feel you  "must  offer an opinion or off topic comment; please do it after trading hours. Charts and signals at signal lines is what we want...and If you feel you do not need to answer questions on this board ...then why are you here.
I-Hub's rules state:  It is the burden of each poster to ensure that their posts do not contain content that qualifies them for removal. It doesn't matter if your post contains the cure to the common cold or the best stock tip since (fill in your favorite ticker here), if it contains other content that is a violation of the site's rules of conduct, then it qualifies for removal.  ...
Thank You...                         You are only as good as your next trade...Kiy
This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will pursue" and similar expressions or variations of such expressions. ...

Albert Einstein 
Create Half a Million $ With $5 a day
Literally everyone can build wealth the tried and true way.

The S&P500 Index, one of many indicator of stock market performance (by tracking big US businesses), averaged 9.5% annual returns from 1928 to 2015 

Now let’s take our $5 a day, which adds up to to $1,825 a year, and put it into an S&P500 or total stock market index or mutual fund. Which just means it should have similar performance, over the long term, as the S&P500’s 9.5% annual returns. We contribute this $5 a day in weekly or monthly chunks (this is important).

You start to accrue both the money you contributed, that $5 a day, and the 9.5% a year returns. Then those contributions and the returns, plus the second year’s contributions, earn another 9.5%. And so on and so fourth. This won’t be the exact case for the year 1 and year 2, because the stock market is SUPER unpredictable in the short term. But in the long term, you can expect decent returns.

After 25 years, we can reach over $180,000 dollars. Your contributions of $5 a day, only make up 1/4 of that total sum. 75% of that is JUST EARNINGS.
After 35 years, we can reach half a million dollars. Can you spare $5 a day for a $500,000 payday? 87% of that is purely earnings!

The Brutal Truth About Today’s World
The Sad Truth About Today’s World Illustrated By Steve Cutts 
Art isn’t all fairytale photoshoots and landscape shots – it can also act as catalyst of change. And Steve Cutts thinks that many things in the world should be different. Work shouldn’t be a grinding, soul-crushing rat race for the almighty dollar. Consumerism shouldn’t hold a vice-like grip on our lives. And social media, well, we need to throw-off the shackles we so eagerly put on ourselves. Wouldn’t life be better then?
 Wish You Were Here           ...Comfortably Numb                         ...... Hey You .....     Brain Damage

                                         .............Us and Them................
Always trade with the direction of the daily CCI 
Swing trades=  Always trade in the direction of the daily bias even for short term trades...if you really feel you must trade against the daily need a hair trigger...get out quick if the position moves against you. The Average True Range for SPX usually runs around 15 points. This range inceases as volatility increases
Remember...What you're looking at on an intraday chart is a daily candle or OHLC price bar "uncompressed" from the daily chart. Kind of a "micro" view of the Macro daily chart...and daily would be a micro view of the weekly chart... 
Front Running a Daily chart signal (...The 60 minute chart can be considered as a proxy for the daily chart and will lead daily chart signals when daily CCI is getting ready to come out of oversold overbought just takes patience to get the timing..) This way; rather than only trade the intraday cycle you can use the intraday charts to front run a daily CCI signal. When the Daily CCI is ready to move out of oversold or overbought... your goal eventually is to catch a trade from intraday that carries over onto the daily chart. It just takes some practice and patience becoming comfortable with the CCI cycles= Intraday/Daily/Weekly and as the 3cycles sometimes line up together= synchronized you may consider a larger position. Best trades will be trades that are trading in the same direction as the daily chart's bias...=Commodity Channel Index CCI 20 points the way...

There is a "Method to the Madness of Crowds" and you can find it and define it on the charts...Technical Charting takes away some of the fear/doubt in trading... and then all you need is patience while waiting for the chart to tell you when the bias/momentum/sentiment turns...listen to signals at signal lines(simple enough...yes?...)...Kiy...

The Market is a giant feedback loop, showing traders (and anyone who views the market) a thermometer reading of the social mood under which traders, and by extension society,  are operating. Most traders seem to think of the market as something that has some external value outside of the price attributed to it by traders. I prefer to think of it as a real-time gauge of a society’s view of their own productive capacity…or more simply put–social moodWhen Markets are understood, the idea that everyone can make money is not only inaccurate but impossible and laughable. Everyone making money means there is no market, because who would be willing to take the other side of the trade? In addition, most traders feel they can move with the crowd to make a (paper) profit, and then get out before the crowd, turning that trade into a real profit. In theory this is sound, but remember everyone else is setting out to do the same thing. It is this crowd movement which allows traders to make money at times. Without a large portion of traders coming to the same decision markets simply would not move. It takes conviction by many traders to create a trend, then it takes euphoric acceptance that “this is the new norm” to end it and “bend it. ” It then takes mass disillusionment to crash it the other way. (

Regression to the Mean is the most powerful law in financial physics
Mean reversions out of extremes are the most powerful and profitable forces in all the financial markets. Riding one has enormous benefits for your wealth.
Financial-market prices and sentiment are like a giant pendulum. The farther they are pulled to one extreme by excessive greed or fear, the farther they necessarily swing to the opposite extreme in the subsequent mean reversion. Like pendulums, these reversions don’t magically stop right in the middle at normal again. Their kinetic momentum carries them through to the opposite ends of their arcs. But overshoot extremes don’t last for long, as the universal greed necessary to fuel them quickly burns itself out.

Markets are not about beliefs, but about sentiment. And, if you can track sentiment, If you can measure sentiment... then you are in a position to make your investment account grow without the need for excuses.  (...this really is all you need to know about the Markets; ...

**** FDA Calender  Price Target fair value
Fair Value (fv) estimates are from
Color Code of stock symbols/letters....MVIS  (T/$3.50H-4.50) example MVIS letter colors indicate the stock price is pointing down and all the letters are boxed in with green= oversold oversold MVIS=MVIS  and you should be looking/considering a long position...(T/$3.50H-4.50) and someone has put a $4.50 price target on it.  (..."T"=target price...the "H" indicates the first target price has been hit...  
Colors are based on reading the CCI 20 (Commodity Channel Index signal lines) ... if "letters" are colored =Green =UP...Red=down...lighter colors = less confident in direction...if letters/stock symbols are Boxed in=Green =oversold=anticipate an "UP" cycle for the CCI 20 indicator or a mean reversion price bounces = at least to centerline within the Bollinger Bands 20,2= the 20 day moving average... and if the box is red=Red=overbought=anticipate a "DOWN" cycle...
§=Reverse of a Signal line(focus is the technical indicator CCI centerline...overbought line +100 and oversold line -100)... ¥= first stock to turn UP/Down after the Group/Sector has been overbought/oversold. Stocks that have a "Target" price are the better choice for a trade...example...MVIS  (T/$3.50H-4.50) a target price with an "H" behind it says the target was "hit" since the target price was MVIS has a second target price of $ if you find MVIS oversold you can consider a long position if you are comfortable with the width of the Bollinger Bands and the target price will give you 10% or more profit... remember this; PRICE= %B and CCI they indicate very much the same and they represent price within the parameters of the Bollinger Bands (box Price inside the Bollinger Bands. The %B tends to lead the CCI signals (a little)...

A few of the more interesting ETFs/Sectors ...Candle Glance Charts= click on the ETF's symbol and you'll get a set of the largest holdings 10-12 stocks in that ETF.
Rising bond yields are good for financials like banks and insurers, but are bad for bond proxies like utilities (and REITs). 
03/15... The Fed hiked rates today as expected, with expectations for two more hikes this year. Judging from immediate market reactions, the Fed announcement is being viewed as somewhat dovish. For one thing, bond yields are dropping. With yields falling, bond prices are having a strong day. Junk bonds, which have been correcting lately, are especially strong. That's also positive for stocks. Rate sensitive stock groups like utilities and REITs are leading a strong market response. Falling yields, however, are weighing on bank stocks. The dollar is also dropping. 
XLF CandleGlance (15.3%)BRK.B,*JPM,WFC, ***BAC (T/$24H-26),C,SPG,USB,CB,*AIG,*GS,
....................................... ZPAS ...PUMP AND DUMP...?
XLK CandleXGlance AAPL,MSFT,FB,T,GOOGL,GOOG,VZ,V,INTC,CSCO .............. ***HDP (T/$21) ... SGH (T/$21) ...QBAK
.........TECZ ...1xBear ...REW ...2xBear... TECS ...3xBear
SMH CandleGlance Semiconductor ...AMD,MVDA,CY,IDTI,IPHI,MPWR,MU,MXIM,TXN,LLTC  ...INTC (T/$40)...AMD (T/$11H-17-22) ... MRAM (T/$19H)... ..........  ICHR (T/$25)(T/$25)...   COHU (T/$25) ... CY (T/$14H-18) ... AMSC (T/$11)  ...SSG...short Semiconductor,,, 

****BOTZ...Global Robotics and Artificial Intelligence.. ISRG 7.9%, MBLY 4.8%,TRMB5.4%,IRBT,BRKS,FARO

WEAR wearable technologies/components IRTC,DXCM,BSX,AAPL,GGNDF,BEAT,KN,TASR,PODD,ABT
wearable devices that will ship this year to enterprise customers from public companies including Fujitsu (OTCPK:FJTSY), Vuzix (NASDAQ:VUZI), Google (NASDAQ:GOOG), and Intel (NASDAQ:INTC). Market estimates vary widely, but a recent report by Grand View Research estimates the enterprise wearables market will be valued at more than $20B by 2025.
SKYY CandleGlance Cloud Computing ...AKAM,ORCL,EQIX,NTAP,AMZN,CSCO,OTEX,JNPR,FB ... YEXT  (T/$14H-18) 4 Brookers like this... XTLY (T/$14H-19)
...............................****TNTR (T/$9-16) Tintri, Inc. develops and markets an enterprise cloud platform combining cloud management software technology and a range of all-flash storage systems for virtualized and cloud environments in the United States and internationally. Its platform provides large organizations and cloud service providers with public cloud capabilities inside their data centers and public cloud services. The company addresses a range of cases, including development operations, disaster recovery and data protection, server virtualization, and desktop virtualization. It also offers its products related support, installation, and training services. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds—to build agile development environments for cloud native applications and to run mission critical enterprise applications. Tintri enables users to guarantee the performance of their applications, automate common IT tasks to reduce operating expenses, troubleshoot across their infrastructure, and predict an organization’s needs to scale—the underpinnings of a modern data center. That’s why leading cloud service providers and enterprises, including Comcast, Chevron, NASA, Toyota, United Healthcare and 21 of the Fortune 100 companies trust Tintri with enterprise cloud..
SNSR CandleGlance  Global Internet Of Things...SWKS,MBLY,GRMN,ST,BRCD,DXCM,JCI,SLAB,BDC,IDCC,ADI ...OTIV (T/$2.25)... MX (T/$13) ..............................NDCVF...SWIR...PTC...ARW...SFE...
IOTS (T/$7) ultra low power (flash) memory., trademark resistive RAM technology called Conductive Bridging RAM (CBRAM®). CBRAM® is a breakthrough technology platform that enables 100 times less energy consumption than today’s flash memory technologies as well as delivering enhanced performance. Visit:
PRNT 3D Printing    DDD  3D Syste mS  SSYS.(T/$24H-33) Stratasys ..   XONE..ExOne.  VJET (T/$6) Voxeljet  ...
......................................MTLS Materialise Sftwre...  DDDX 3D Ind ... HPQ sftwre
3D Printing Jan 2017  International Data Corporation (IDC) Worldwide Semi-Annual 3D Printing Spending guide is predicting that the rapid expansion of the 3D printing industry is expected to continue without slowing down. According to the IDC analysts, global revenues for the 3D printing market will explode to a massive $35.4 billion by the year 2020. With 2016 revenues expected to reach $15.9 billion which means the industry could nearly double within the next five years
 IYZ Telecom... T,VZ,TMUS,CLT,SBAC,LVLT,S,FTR,SHEN ....TDS....(WIN ... RNG... QTNA (T/$24-28) SONS (T/$10)
PXQ Networking... QCOM,APH,AAPL,CHKP,CSCO,VMW,CA,CTXS,FNSR,BLOX ...GIMA,LOGM,... SSNI  (T/$11H-14)Smart Grid... QTNA (T/24-28) SHOR (T/$10)


CGW Global Water Index... AWK,DHR,XYL,IEX.......  (CDZI...Water Utility)
TAN...Solar CandleGlance FSLR,SCTY,GCPEF,TERP,TSL,SPWR,CAFD,ABY ...  RUN  (T/11) SEMI... VSLR (T/$6h)... SUNW (T/$2.50)
 ENPH (T/$1) Enphase’s new IQ microinverters
 WNDW  Disruptor and upstart SolarWindow Technologies, Inc. (Symbol: WNDW) has developed transparent electricity generating coatings that can go onto any glass surface, such as windows or sunroofs. Imagine a Tesla being able to top off its batteries while on the road. And since these coatings generate electricity under natural, low and even shaded light conditions, that Tesla could be charging up all day.
 The inflation pipeline has three stages. The first stage is the price of raw materials. The second stage is the price companies pay for raw materials (producer price inflation). The third stage is what companies charge consumers for their products (CPI inflation). It all starts with the direction of commodity prices. Strangely, that's the part that economists (and the Fed) pay no attention to. How can economists expect to predict the final stage of CPI inflation, if they ignore the first stage which is the direction of commodity prices?  ...John Murphy
 ECSIF eCobalt Solutions... Cobalt metal

Speculation Stocks 
“Promoted stocks tend to rise because of the work of the stock promoter. But, later on, usually share price declines when the promo dollars dry up. Thus, buyers beware! The share price could keep creeping up as more emails are sent out and new market participants buy shares. Some will make money. However, in a few days, weeks or months, the stock promotion will stop or the exchange will warn the market about it, and the share price may fall sharply. 
Just be careful... Pumps & Dumps 101
This is your brain on stocks  

5 Brain Flaws that make you a lousy investor
*****Virtual Reality/Augmented Reality/Artificial Intelligence    In the real world, Artifical Intelligence9(AI) will enter our lives in three phases and forms:
PHASE #1 Assisted Intelligence: AI that replaces repetitive and mundane tasks traditionally done by humans. A timely example would be the proliferation of robots used at Amazon to “pick” items from warehouse shelves, which we mentioned in last month’s issue. You’ll recall we’re already double-digit gains in the space (with more to come) in the Robo Global Robotics & Automation ETF (ROBO) and Cognex Corp. (CGNX).

PHASE #2 Augmented Intelligence: AI that incorporates machine learning to supplement and support human analysis. One area where this type of AI is being implemented is legal discovery. That is, the period of time in which both legal parties gather evidence. Seventy-five percent of the costs associated with discovery are tied to human review of documents. And people are expensive. Using AI to pre-screen — and reduce the amount of relevant documents before humans even start reviewing the files — can dramatically reduce costs. We profited from this very technology when our portfolio position Epiq Systems was acquired for a 40% gain in July 2016.

PHASE #3 Autonomous Intelligence: AI that takes over for humans in a highly specific task. Self-driving cars would be the ultimate example of this in action.

AI appears on our smartphones, with personal assistants, augmented and virtual reality headsets, robots, in data centers, and in semi and fully autonomous vehicles.

AI will be dominated by the big names such as Apple, Amazon, Alphabet Google, Facebook, and Samsung; however some smaller names like Nvidia and AMD can also do well.

AI will be invisible, yet it will be everywhere.
AI = "machines with brains"

AMD (T/$20) Advanced Micro Devicesis a semiconductor manufacturer. The company's new AI chips are the Radeon Instinct series. AMD is also racing to put its chips into AI applications. AMD will release its ROCm deep-learning framework, as well as an open-source GPU-accelerated library called MIOpen. The company plans to launch three products under the new brand in 2017.
AMD Advanced Micro Devices, Inc. daily Stock Chart
Softbank (OTC:SFBTF)(they bought out chip designer ARM, and own 4.95% of Nvidia)
  • Applied Optoelectronics Inc. (NASDAQ:AAOI) - Design and manufacture high speed data and fiber-optic network products, such as transmitters and receivers. 2017 PE is 14.2, and 2018 PE is 12.6 representing excellent value for a growth stock. Analyst consensus price target is US$75.78, representing 23% upside. 
AAOI started 2017 with monthly production of lasers which go into the multiplexer or transceiver modules at a rate of 300 per month. They announced production will ramp to 1 million per month by year end. In the first quarter 2017 average production was 400,000 per month. May 2017 production was up to 600,000 per month, 50% above 1Q2017. AAOI has the highest margins of all the competition. Positive cash flow. Lowest cost structure with plants in Texas, Taiwan and China. 

  • Fabrinet (NYSE:FN) - Design and manufacture transceivers, transponders, optical amplifiers, lasers, and sensors. 2017 PE is 13.7, and 2018 PE is 12.2 representing excellent value for a growth stock. Analyst consensus price target is US$52.55, representing 23% upside.
    Others in this sector which are more telco focused include NeoPhotonics (NYSE:NPTN), Oclaro (NASDAQ:OCLR), Finisar (NASDAQ:FNSR), and Lumentum (NASDAQ:LITE). 
    MU, memory based processing is the future.
It is no secret that Automotive makers are racing each other to mass produce the first autonomous car. To achieve fully autonomous driving, cars need to have a variety of sensors to perceive near and far fields of visions in every direction. The sensors include radar, LIDAR, ultrasonic, cameras, and night vision devices. The data collected by these sensors are fed into highly complex System on Chips (SoCs) with compute performance that is equivalent to what only supercomputers could deliver a few years ago. Complex, state of the art algorithms that are increasingly based upon artificial intelligence ensure vehicle, driver, passenger, and pedestrian safety based on factors such as traffic, weather, dangerous conditions, etc
Next level memory is an integral part of AI. I recommend you getting up to speed on the demands we're talking about in memory today. this is not about storage capacity. this is about on demand, real time access to data that has to solve a problem immediately. This is 
the next level of memory that only 2 or 3 companies can do. It's a workload solution not just a storage solution. think about a car that needs to calculate what is happening around it immediately. thats not a storage solution, thats a storage plus speed and cross referenced access in real time. only 3 or 4 companies in the world have this capability and innovation, and Micron is one of the only american ones. This is why Nvidia and Intel are partnered with Micron. here is a great discussion about it:


02/28/17 ...potential profits in the VR/AR industry are enormous. Goldman Sachs (GS) estimates that the market will reach $80 billion by 2025, with the potential for that figure to actually soar much higher, to more than $180 billion.
Many of the companies developing VR/AR hardware and software are among the biggest names in Silicon Valley including
 Apple (AAPL), Alphabet (GOOG), Amazon (AMZN), Facebook (FB) and Sony (SNE). Autoliv ALV
On a July 26, 2016 conference call with analysts, AAPL's CEO Cook said he was bullish about augmented reality. "AR can be really great, and we have been and continue to invest a lot in this," Cook said. "We are high on AR for the long run. We think there are great things for customers and a great commercial opportunity." In September, Cook told ABC News that augmented reality presented a bigger business opportunity than virtual reality. "There's virtual reality and there's augmented reality — both of these are incredibly interesting," Cook said. "But my own view is that augmented reality is the larger of the two, probably by far."

Augmented reality superimposes digital images in a person's field of vision. It provides the user with information for navigation, to complete tasks and other purposes. By contrast, virtual reality is an immersive media that places the wearer of special headsets into a completely digital world, mostly for entertainment purposes. In November, Bloomberg reported that Apple had already ordered "small quantities of near-eye displays from one supplier for testing." It said Apple was in the exploration phase of wearable computing. The device being tested would connect wirelessly to the iPhone. Also in November, KGI analyst Ming-Chi Kuo said Apple is looking to leapfrog the competition in AR by three to five years with its offering. But Kuo said it could take Apple one to two years to come out with an AR product.
 In the Year 2525 ....Sony Facebook's Oculus virtual reality device Samsung, Microsoft Hololens...Google Glass 
Head worn devices...ZBRA Zebra Technology... INTC Intel...FJTSY Fujitsu...

Sales of virtual reality and augmented reality headsets will surge by 2021, when 100 million a year of the devices may be sold, according to a new report by research firm IDC.
Zion Market Research forecasts that the global AR market will grow at an annual pace of 85% until 2021, hitting a size of $134 billion. 

HIMX (T/$6H (H=hit $6 targeT)-10 now T/$12) 07/14 Oppenheimer downgrades Himax Technologies (NASDAQ:HIMX) from Perform to Underperform with a $4 price target....hyped as the I-PHONE KILLER(I really don't know why...semicndtr, display driver integrated circuits (ICs), timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation, et al...The company is ramping up for more sales of its liquid crystals on silicon (LCOS) and wafer-level optics (WLO) products for AR devices after ramping up production for both later this year and into 2018. Himax says that the ramp-up is because its AR customers are looking to their next generation devices, and that Himax's tech will benefit from that. (buy after 2nd quarter 2017...) you may want to wait even longer... Himax management is talking about having a lot of smartphone customers coming in and requesting support for WLO, but the talk needs to translate into revenue growth later in the year. For now, the company's guidance doesn't match management's optimism: The midpoint of its second-quarter revenue guidance indicates that Himax's top line will drop almost 25% year over year. Analysts aren't too optimistic about Himax's performance, either, as they project a 17% revenue decline for fiscal 2017, which will lead to a weak earnings performance. At the same time, Himax is quite expensive, at 36 times last year's earnings, way higher than its 13-year median price-to-earnings ratio of 17. What's even more surprising is that Himax shares could become more expensive in the next year. Wall Street projects a forward P/E ratio of 48, thanks to a potential drop in earnings.Investors, therefore, should adopt a wait-and-see approach despite the hoopla around AR technology. Himax shares seem to have run up too fast this year, driven by rumors and speculations, not by any concrete financial gains.

*****KOPN  (T/$3.70H-5)  Kopin Corporation semicndtr...wearable technologies and display products...develops, makes and markets virtual and augmented reality gaming, training, and simulation products. Kopin’s Whisper Voice Chip, Solos smart glasses and Pupil LCD display modules will be among the Kopin products displayed on the CES show floor. 

Kopin has transitioned to a wearable-centric company - they have positioned themselves to be entirely levered to success in Enterprise and Consumer head-worn AR with components and licensable IP.

When you combine high level AR market forecasts with Kopin's device share dominance with design wins inside 5 Industrial AR headsets, I believe it is clear this stock is the one to own if you are looking to lever your portfolio to the massive growth possible in the head-worn wearable segment.

As I have noted previously and pointed out in my blog posting "The Wearables Acquisition Intel Needs To Make - And Fast!" I believe a current reasonable market capitalization value for Kopin would be $394M or north of $5.00/share based on the following:

 "The Wearables Acquisition Intel Needs To Make - And Fast!" I believe a current reasonable market capitalization value for Kopin would be $394M or north of $5.00/share based on the following:

  • IP portfolio I have valued at at least $300M: Kopin holds over 300 granted & pending wearables patents; I believe they possess the strongest head-worn wearables IP portfolio in the industry

*** LPL  (T/$16H-20)  LG Display
MVIS  (T/$3.00H-4.50)  Microvision makes PicoP scanning technology for three-dimensional sensing and image capture.
IMMR (T/$8H-13) Immersion Corporation...the creation of the sense of touch to the user through the use of vibrations or motions. Immersion is one of the leaders in this technology, also known as kinesthetic communication. (very weak guidance for all of 2017)
*****OCLR  (T/$11H-15)  lasers and optical components partner with CEIN...Oclaro provides differentiated solutions for optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, application virtualization and other bandwidth-intensive and high-speed applications....

 NPTN  (T/$13-17)  NeoPhotonics high speed digital optical signals...  FN ...*FNSR (T/42) ... 
SIGM (T/$8) Sigma Designs, Inc. provides integrated system-on-chip (SoC) solutions and intelligent platforms for use in various home entertainment and home control appliances.
STM (T/$20),
 ***** VUZI (T/$11)  VUZI smart glasses ...
****NEON (T/$3.50)  touch screen and ability to sense an object's size,deph,velocity, pressure, proximitty to any type surface....
SYNA ...ACIA... AAOI...  LITE (T/45H) ... 
BBRY (T/$13-15) BlackBerry..."When Wall Street shifts its frame of expectations toward the future, and gets over their legacy business, watch out." The company has high expectations for BlackBerry's QNX secure industrial operating system and future sales. QNX is a self-driving car software and so far, has been installed in already more than 60 million cars. Ford's Sync 3 infotainment system runs on it as well as Audi's TT virtual cockpit. According to the Citron report, BlackBerry's QNX far exceeds the 16 million units that Mobileye has installed, a rival autonomous vehicle tech company that Intel Corp said it would purchase for $15.3 billion.
INTC (T$38-42) (fv$41.80)..Buying as of03/13 =Mobileye...*MBLY Triple Digit Stock  develops computer vision/machine learning/data analysis/localization/mapping for advanced driver assistance systems and autonomous driving technologies primarily in Israel.... Mobileye...We believe the stock’s reaction to the Tesla news was an overreaction because 1) Tesla comprises about only 1% of Mobileye’s revenue today 2) Mobileye said that of its $1.1BN 2019 revenue target, Tesla contributes ~2% (or ~$17MM on 350K cars).” Anderson sets a $60 price target; the stock is rebounding, up $2, or 4.4%, at $47.33. Anderson writes that his own digging suggests the split had been in the works for some time, and that graphics chip maker Nvidia (NVDA) is likely being tapped by Tesla to produce an alternative: Our sense from talking with industry sources is that the relationship between Mobileye and Tesla has been headed to this outcome for some time. We believe Tesla would like to push the envelope more with autonomous features and increasingly with their own algorithms. Our best guess at this point (based on our checks) is that Tesla will eventually migrate to a hardware solution from Bosch with processing done by Nvidia using internally-generated Tesla algorithms.

Intel (NASDAQ:INTC) has been very active acquiring companies involved in the burgeoning wearable technology segment. You will find a great overview from Matt Margolis in his article entitled, "Intel Is Quietly Emerging As The Augmented Reality World Leader." Despite this acquisition activity, there are still significant gaps if Intel wants to repeat the "Intel Inside" strategy for wearables that it so successfully employed in the PC era.

In my opinion, these are the missing pieces from Intel's current wearables ecosystem:

  • Proven high yield micro display and complementary optical technology
    Next generation noise cancellation hardware and software
    Head-worn reference designs - the new Intel Inside motherboard!
    Licensable user interface IP covering voice and gesture input methods
    Software middleware or a wearables operating system
    Broad wearables patent protection

Interestingly, there is a way for Intel to achieve gap closure in all of the areas above with a single transaction: they could acquire Kopin Corp. (NASDAQ:KOPN).

Assuming Intel is as interested as I think they should be, what would this transaction look like and how can we benefit?

General Motors announced it will begin offering unlimited data for owners for just $20 per month. That’s a steal, considering rates for in-car data started at about $500 for 30 gigabytes in 2014. Considering the average person spends 42 hours per year in traffic — and upward of 80 hours in major metropolitan areas — the car represents the next battleground for media and telecom companies. In short, there’s a lot of revenue up for grabs — over $80 billion by 2021. The sooner companies can get consumers to start connecting in the car, the more market share they stand to capture. Bottom line: Price is always a barrier to adoption. But GM just eliminated it.  ...5G networks promise to offer 10–100 times faster data speeds and lower latency. Our recommendation of PCTEL stands to benefit as initial rollouts begin, since it sells equipment vital to testing new wireless networks. However, 5G network progression also bodes favorably for our investments in the internet of things, virtual personal assistants, connected cars and associative computing. Faster processing speeds make these technologies more compelling. That includes Memex Inc. (OEE:TSX-V), Control4 Corp. (CTRL), GSI Technology Inc. (GSIT) and Visteon (VC). So keep buying

VSH ...(T/$15H=16.25) Vishay Intertechnology ...broadens its optoelectronics portfolio with the introduction of a new high speed silicon PIN photodiode with enhanced sensitivity for visible light. Vishay Semiconductors VEMD5080X01 offers fast switching times and low capacitance for precise signal detection in wearable devices and medical, industrial, and automotive applications.
*ISNS ... Image Sensing Systems, Inc. develops and markets software-based computer enabled detection products and solutions for the intelligent transportation systems industry. Its video and radar processing products are used in traffic, security, police, parking applications, such as intersection control, highway, bridge, tunnel traffic management, venue security, entry control, LPR, traffic data collection. 
**NVDA  Nvidia neural imprinting and all forms of virtual reality...  ...Tesla’s co-founder and CEO, Elon Musk, has promoted NVIDIA’s GPUs as a key element for driverless car technology. At the 2015 GPU Technology Conference last year, Musk said that what NVIDIA is doing with its Tegra GPU’s will prove “really important for self-driving in the future.” While Tesla uses NVIDIA’s GPUs, it doesn’t currently use NVIDIA’s Drive PX system, though there’s no reason why it couldn’t in the future. Why all of this matters for NVIDIA investors NVIDIA’s self-driving car focus is becoming increasingly important because of the technology’s quick adoption by both automakers and consumers. IHS Automotive estimates that between now and 2035, there will be 76 million vehicles on the road with some level of self-driving capabilities. Cheaper technology is spurring growth, as is evidenced by Honda’s $20,040 Civic, which can drive itself on the highway. The driverless-car market is expected to grow to $42 billion by 2025, according to Boston Consulting Group, and it’s clear that NVIDIA’s mapping out a plan to grab as much of that market as possible with its current automotive partnerships.

 PCTEL Inc. (PCTI) and Visteon Corp. (VC).

VOICE  ... the iPhone kicked off what can affectionately be dubbed the “Touchscreen Era.” But the sun is setting on that period. We’re now entering the “Smart Voice Era.” And once again, it’s being pioneered by Apple and its introduction of a virtual assistant in 2011. Very soon, the days of pulling your smartphone from your pocket... swiping to unlock it… opening an app… and then tapping what you want will seem burdensome. Instead, just speak your desire into the air — anywhere — and it will be done. Thanks to key advances in artificial intelligence, voice interfaces can now learn in real-time, enabling them to accomplish an ever-increasing number of difficult and nuanced tasks. 
companies like Nvidia and GSI Technology Inc. (GSIT) are at the forefront of this development.
******GSIT  (T/$9H)  Remember how Nvidia leveraged the benefits of “parallel processing” to net windfall sales and profits for investors in 2016? Well, GSI’s in-place associative computing chips will leverage “massive parallel processing” capabilities. Think Nvidia on steroids.

Key Tasks Currently Accomplished by Voice Assistants ? Check Or Add an Item to Calendar ? Place an Online Order ? Send a Hands-Free Text ? Set an Alarm ? Conduct an Internet Search ? Read the News ? Get a Weather Forecast ? Play a Song ? Control Smart Home Devices (Thermostat, Lighting, etc.) ? Get a Traffic Update ? Check Spelling ? Call an Uber ? Add Something to a To-Do List
****DSPG (T/$15) DSP Group Inc. (DSPG) is a leading provider of digital signal processing chips. Its core knowhow is enabling better voice communications. HDClear solution. It’s a comprehensive noise-suppression and voice quality-enhancement chipset for mobile devices. HDClear incorporates the company’s proprietary noise-cancellation algorithms to deliver unrivaled voice quality in any situation. And it does so using very low power, which is a key consideration for device makers. Simply put, HDClear enables voice interfaces to hear clearly and process commands efficiently. No matter how noisy the environment. Management estimates there are currently over 2 billion potential devices that could benefit from its HDClear chipset. And they’re not wasting any time capturing that upside potential. Case in point: New product sales increased 48% in 2016. And they’re headed higher still, as DSP secured two design wins in the voice interface market. These will enter mass production in the second half of 2017. With over 30 years of voice processing expertise — and 227 patents and applications — we couldn’t ask for a better-positioned company to benefit from the rapid transition to voice interfaces. A Rapidly Growing and High-Probability Pipeline: DSP’s new engagement pipeline for HDClear covers voice-enabled products in every product category — IoT, smart assistants, PCs, wearables, smart speakers, home appliances and automotive. As management said, “We are excited with the market dynamics and the greenfield opportunity in the voice activation and control space.” Given DSP’s technology leadership, it’s only a matter of time before these opportunities are converted into design wins. But don’t just take my word for it. As management confirmed, “We actually feel a lot more bullish about our ability to penetrate and get design wins in this market.” Naturally, more design wins will lead to steadily increasing sales — and, in turn, profits. Speaking of which… New Products Already Driving Growth and Margin Expansion: After debuting with gross margins in the high 30% range, last quarter they increased to 56.6%. Higher margins lead to higher profits, which ultimately leads to higher share prices.

*****HEAR (T/$1.90) 4D sound...

08/14*****XGTI (T/$3.50-4)  xG Technology a leading provider of wireless video solutions to broadcast, law enforcement and defense markets, and private mobile broadband networks for critical communications"The recent acquisitions of Vislink and IMT position XGTI to lead the market for wireless video broadcasting systems, in our view. We expect an approximately 10-year, $2.0 billion hardware up-fit opportunity as a result of a recent spectrum auction to drive accelerated growth in 2019, and as the market share leader, XGTI is positioned to benefit." In addition, "We expect share gains in the company’s satellite communications business to be a key growth driver."

Semi/Cloud/Biometrics ...  
***ADI... Biometrics, drones..semicondtrs
****ANY () tech. cloud, storage...July 11 did a 1 for 25 reverse split
CNIT..Internet service company that provides cloud-based platform China... ****SFUN (T/$9)  Chinese real estate Internet portal 
CUDA (T/$25h-29) Barracuda ... cloud-enabled solutions that enable customers to address security threats, improve network performance, and protect and store their data. It provides various security solutions, including Barracuda Email Security (01/09 earns/profit beat)
EIGI  (T/$10.50)...
***FTR  (T/$)telecom fiber-to-the-home and cloud backup, sharing, identy protection...
**GSB () software cloud based ...
08/02 ****HIVE (T/$9-10) cloud-managed mobile platform...
MODN (T/$16) ...provides revenue management cloud solutions for the life science and technology industries
*NXTD (T-$4) biometrics security mobile devices, electronic wallet  virtually any magnetic stripe card allow single electronic card to replicate cards for  MobileBio VoiceMatch ...

****STM (T/$14H-$20)  STMicroelectronics Semicndctr 
XTLY (T/$15-20) incentive compensation solutions for employee and sales performance management 
***PSTG  (T/13H-15) Provides flash memory-based enterprise storage hardware...

 ****USAT (T/$6) wireless networking, cashless transactions, asset monitoring...
Radio Frequency Identification (RFID) isn't just a gamble. It's real, and the stakes are high. Identifying worthy players in disruptive technologies. Motley Fool
ROP ...Roper Technologies ... Roper makes a wide array of products including water meters, energy pump testers, and medical imaging equipment. Roper makes  RFID equipment used at tollbooths to facilitate the reading of prepaid express passes. This is naturally a booming market. The days of bypassing tolls are long gone as cars are scanned through tollbooths, and the fact that RFID technology requires fewer tollbooth operators is gravy to controlling costs. 
ZBRA  Zebra Technologies (NASDAQ:ZBRA) -- Using RFID to track inventory is made easier through Zebra's solutions. It offers mobile and handheld readers as well as fixed readers. It also makes reader antennas to send data across various points of business activity. Zebra is also a leading distributor of RFID printers that allow businesses to encode and print out the RFID-backed labels that can be tracked with its readers.   
GPIC  Gaming Partners (NASDAQ:GPIC) --  The company makes gaming equipment, and that included at the time a thriving business embedding RFID microchips in casino chips to facilitate immediate inventory tallies and prevent counterfeit currency. It continues to offer RFID readers for cage, table, and vault applications as well as RFID technologies for casino readers. RFID isn't just a gamble. It's real, and the stakes are high. Identifying worthy players in disruptive technologies

 Other Tech Stocks
***PRCP (T/$11)  Perception Inc... 3D scanning products, laser scanners ...
*CPST Capstone Turbine... microturbine...

*****WATT WATT  Energous...wire-free charging of electronic devices at a distance...
As for the iPhone 8, one of the main rumors so far is related to the inclusion of wireless charging technology in the phone. Wireless charging is an interesting concept, and current options rely on magnetic energy to charge, requiring users to place their device on some sort of compatible pad. Energous Corporation WATT, an innovative wireless charging company that uses RF waves to charge. Energous promises “long-distance” wireless charging, and many people think the company could be teaming up with Apple to incorporate the tech in the iPhone 8. (

IWSY  ImageWare Systems...biometrically enabled software-based identity management ... 
AMBA (T/$84)... Ambarella produces systems on a chip for various camera applications such as GoPro action cams and drones. These chips incorporate numerous patented technologies that allow them to work with very low power, in low ambient light conditions, and with highly efficient compression capabilities. 
PI (T/$40H)  Impinj frequency ID chip-maker, maker of RAIN RFID chips which helps supply chains frictionlessly track items...
MU Micron is the third largest mobile DRAM and fourth largest NAND manufacturer in the world. It's arguably the most straightforward play on the memory-chip market for investors, Samsung Electronics (NASDAQOTH:SSNLF), and Western Digital (NASDAQ:WDC)  icron is currently developing next-gen memory technologies such as 3D NAND and 3DXPoint with Intel (NASDAQ:INTC),

BIO/Pharma/Medical ... President Donald Trump has stated on multiple occasions that he plans to eliminate restrictions on drug development for the FDA. This policy would positively affect biomedical companies, as their products would reach the open market more easily and frequently. Certain biomedical companies will pose a stronger investment as the FDA revises their drug development standards.

With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year.

ABEO Abeona Therapeutics ...
AEZS (T/2H -4 FOR 2018) AEterna  FDA has accepted the drug maker's New Drug Application (NDA) for Macrilen (macimorelin), a novel orally-active ghrelin agonist intended to help in monitoring treatment for adult growth hormone deficiency (AGHD)
ALIM (T/$3-5) Alimera Sciences... The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. 
****08/03 ...ACHN (T/$6-10)...Achillion Pharm ... 
****08/11 ADMA (T/$13) ADMA Biologics  plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia.
Adamis has a vision for its Epinephrine Pre-filled Syringe “PFS," which is designed as a cost-friendly alternative for those suffering from anaphylactic reactions. The drug maker hopes to compete with the likes of Mylan's EpiPen that has been raking in billions. Late last year, generic pharmaceuticals giant, Mylan (NASDAQ:MYL) found itself caught in the crosshairs of a nationwide controversy involving steep increases in the pricing of its life-saving drug injector, EpiPen. Since 2009, the price of an EpiPen two-pack has risen from $100 to over $600 today. These results have been great for Mylan's financials, as last year, EpiPen was responsible for approximately $1 billion in revenue and accounted for 40% of Mylan's total operating profits. But it has been a public relations nightmare. On the backs of this controversy, Mylan reacted by announcing that the company would be launching a generic version of the EpiPen late last year. This generic version would be priced at half the cost of the branded EpiPen -- around $300. Even so, at half the sales, this would still be a $500 million indication. And one tiny biotech is chomping at the bit in its efforts to dethrone Mylan's EpiPen empireWith the FDA's decision expected on June 15, Maxim analyst Jason Kolbert seems to not be concerned by the Complete Response Letter the company received from the regulator last year. While the FDA expressed concerns and pushed the firm to work on expansion of the human factors study, Adamis has since handled these challenges successfully. The expansion was just a "low hurdle" to the analyst, as he does not see this to be a meaningful roadblock in any way to Adamis' success. The analyst is also excited about the market opportunity the company is pursuing, noting, "We see a billion dollar market, and in Adamis PFS a superior product [...] If Adamis can acquire just 10% market share and generate sales approaching $100M (which we believe is the low end), it suggests shares are undervalued." Ultimately, Kolbert believes Adamis' valuation is compelling. As such, the analyst reiterates a Buy rating on Adamis shares, with a $10.00 price target, which implies 185% potential upside from current levels
*****ADXS (T/19-24) Advaxis ...Its LM therapies alter live strains of Listeria monocytogenes bacteria to generate cancer-fighting T cells targeting cancer antigens. Clinical trials have shown these immunotherapies to be well tolerated with anti-tumor activity, which could translate to a successful product or partnership in the future if successful in later trials. The downside is that the firm continues to burn cash as it develops its clinical pipeline...  Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

ALDR () ...Alder Biopharmaceuticals... A wave of new preventive migraine medications are on the horizon.The migraine market is huge. An estimated 38 million Americans have migraines — and Dr. Eric Pearlman, a medical fellow at Lilly, one of the companies developing these treatments, told Business Insider that about 15 million of those migraine sufferers would be eligible for preventive treatment. Alder Biopharmaceuticals, eptinezumab which would be administered on a quarterly basis, is in phase 3 trials. The company plans to submit to the FDA in the second half of 2018.

AMAG () “Severe preeclampsia can be a life-threatening condition and is a contributing factor in a significant number of preterm births in the U.S., yet no FDA-approved treatment options currently exist,” said Julie Krop, M.D., chief medical officer and senior vice president, clinical development and regulatory affairs at AMAG. “The development and potential approval of DIF for the treatment of severe preeclampsia could have a significant impact on the lives of high-risk pregnant women and their babies, and the therapy would nicely complement AMAG’s existing portfolio of maternal health products.”
***APDN  (T/$6) (fv $1.05) Applied DNA Sciences Inc. 

AKTX (T/$6) Akari Therapeutics... focuses  on therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome.

**ARNA  (T/) ...weight loss drug...pulmonary arterial immune disease...ulcerative colitis

****AUPH (T/$10-14) ...treatment lupus nephritis duration-of-remission data from a mid-stage study that's good enough to suggest it could eventually change how doctors treat kidney failure in lupus patients. In the United States, there are over 500,000 people with systemic lupus erythematosus (SLE), and up to 60% of these patients will develop LN, or inflammation of the kidneys that can lead to end-stage kidney disease. Today, patients with LN are treated with steroids and CellCept, but for many patients this approach falls short. Steroids can result in unwanted side effects, and CellCept's efficacy can be hit-and-miss.Because current treatments are inadequate, there's an important need for new treatments, and based on Aurinia Pharmaceuticals' trial data, that need may be addressed by voclosporin. Earlier this year, the company reported that adding voclosporin to CellCept improved patient response rates and reduced patients' need for steroids. Specifically, the two-drug combination delivered a complete response rate of 49% at the 23.7 mg dose that was far better than the 24% complete remission rate observed in the trial's control group.
AVEO (T/$3)
*******AVXL (T/$15) Anavex Life Sciences ...drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of Alzheimer's disease; and preclinical stage to treat Parkinson's disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain.
*****AXSM (T/$14-18) (fv $4.79) track designation Tx for agitation in patiennts with alzheimer disease...
****CAPR (T/$2) Capricor Therapeutics, ...granted FDA Rare Pediatric Disease Designation for CAP-1002, the company’s treatment for Duchenne muscular dystrophy (DMD) and cardiology indications. In reaction, CAPR stocks soared by 132%.
CBAY (T/$12-15) ...liver disease...
**BLFS  hypothermic storage and cryopreservation cells and tissues, reduce post-preservation necrosis and apoptosis...Bothel,Wa.
07/31  BLPH... new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD). “Pulmonary Hypertension with IPF or COPD has no approved therapies and has been associated with increased hospitalizations and mortality.  The therapies used in other pulmonary hypertension populations, which act systemically, have failed to show a benefit for these patients, creating a critical unmet need for effective and safe long-term treatment options,” said Prof. W. De Backer MD, Director in the Department of Pulmonary Medicine, University Hospital and University of Antwerp. “Pulsed iNO has a potentially unique and distinguishing advantage as the data from these trials shows that it can provide selective vasodilation to the well-functioning parts of the lung, allowing for improvement in hemodynamic measures as well as increased exercise capacity without worsening oxygenation.”
BLRX (T/$3)... stem cell etal... 
BVXV () ... focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company offers M-001, a synthetic peptide-based protein, which is in Phase 2 clinical development stage targeting seasonal and pandemic strains of the influenza virus. Phase-3 inTandem3 clinical trials The study demonstrated that sotagliflozin 400 mg was superior to the placebo in the patients with A1C <7.0% at Week 24. The study also did not record any episode of severe hypoglycemia or diabetic ketoacidosis (DKA) after randomization. Severe hypoglycemia is a diabetic emergency where blood glucose level becomes so low that patients need help from another person for treatment. Diabetic ketoacidosis is a serious diabetes complication where the body produces excess blood acids (ketones).
 “Strategy for approving a universal flu vaccine” in the journal Future Virology (Ben-Yedidia et al., 2017). The authors discuss the strategy to get M-001 through the regulatory process by using a stepwise approach that first utilizes an existing regulatory marker before using newly defined markers.  
Currently, the efficacy of all seasonal influenza vaccines is tested based on induction of hemagglutination inhibition (HAI) antibodies that target the outer variable regions of the viral hemagglutinin protein. Since M-001 is targeted against conserved regions of the influenza virus, it does not elicit HAI antibodies but instead induces a cellular response. Thus far, BiondVax has taken the conservative approach of using M-001 as a primer to be given ahead of the seasonal influenza vaccine. This has allowed the HAI antibody response to continue to be used to verify the efficacy of M-001. When given has a primer, M-001 enhances and broadens the HAI antibody response induced by the seasonal influenza vaccine.
CDTX (T/$11-14) ...class of antifungals for the treatment and prevention of serious, invasive fungal infections. The company also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid. In addition, it develops a proprietary immunotherapy technology platform Cloudbreak, which is designed to create compounds that direct immune system to attack and eliminate bacterial, fungal or viral pathogens.
CATB (T/$4-9)...Cystic Fibrosis
CBAY (T/$15)  liver disease...most significant was the lack of safety concerns associated with the drug
****CBIO (T/$11)  focuses on developing medicines to address hematology indications, ... hemophilia
****CERS (T/$7-9) ommercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally
CLBS  (T/$7) ...provides development and manufacturing services to the cell therapy industry in the United States... also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. 
****CNAT (T/$9)  treat liver diseases
*****CHRS (T/$40) Coherus BioSciences, Inc. shares dropped sharply to close the week down 28% to $14.85 following its announcement that the FDA issued a CRL (Complete Response Letter) for its Biologics License Application (BLA) for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate. No further trials were requested by the FDA and the company expects to respond to the agency in the coming months. 
The market for biosimilars  -- drugs designed to be interchangeable with branded biologically based medicines -- is expected to become one of the fastest-growing segments of the pharmaceutical industry over the next decade. After all, there is $100 billion worth of biologically based drugs on the market that have either lost exclusivity or will lose patent protection by 2020, according to a report by Markets and Markets. Unfortunately, there aren't a lot of great ways for American investors to gain direct access to this emerging market. The late-stage biologics company Coherus Biosciences, however, is one glaring exception.
Coherus is presently working on resolving the outstanding issues regarding its regulatory filing for a biosimilar to Amgen's megablockbuster bone marrow drug Neulasta. The good news is that U.S. Food and Drug Administration reportedly isn't going to require the company run any additional trials in order to refile its application. So, depending on the nature of all the outstanding issues, Coherus could have an FDA-approved biosimilar for a top-selling drug on the market within the next twelve months.  Although it's hard to say how much of the Neulasta market Coherus can actually capture with its copycat medicine, the drugmaker's shares should get a nice boost even if it only goes on to grab a couple hundred million dollars in annual sales at peak. Coherus, after all, presently sports a market cap of a mere $794 million following its latest dip in the wake of that regulatory setback. In all, Coherus is well-positioned to take advantage of the rapidly evolving biosimilar market, making it an outstanding growth play for savvy investors
Coherus is researching copycat versions of a handful of multi-billion dollar drugs, including Amgen's Neulasta and Enbrel as well as AbbVie's Humira. If Coherus succeeds at bringing one of these drugs to market and can steal even a small amount of market share then it could be a financial bonanza for the business.
*****CMRX (T/$8) (fv $7.65oral antivirals herpes virus and adeno virus. 
****CNAT (T/$9-18) ...Liver disease
****CTRV (T/$4) Hepatitis B
CYTR (T/$10)  scleroderma etal...
DRRX (T/$3) Durect Corp...

***07/28 and 08/10  DVAX Dynavax hepatitis B vaccine, skin cancer
EBS...(T/$40) Emergent BioSolutions,Biodefense division... BioThrax to treat anthrax disease; Anthrasil treatment of inhalational anthrax; BAT treat botulinum disease; VIGIV address adverse events from smallpox vaccination; RSDL removal or neutralization of chemical agents, T-2 toxins, and various pesticide-related chemicals from the skin. NuThrax, next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 compound in the EV-035 series of broad spectrum antibiotics for Burkholderia pseudomallei; VAX161C, a recombinant pandemic influenza vaccine; PreviThrax, a recombinant protective antigen anthrax vaccine, as well as other products addressing public health threats and emerging infectious diseases. Its Biosciences division markets IXINITY prevent bleeding episodes in people with hemophilia B; WinRho SDF treat autoimmune platelet disorders and hemolytic disease of the newborn; HepaGam B post-exposure prophylactic treatment of hepatitis-B; VARIZIG post-exposure prophylactic treatment of varicella zoster virus. This division's investigational stage product candidates include otlertuzumab, protein therapeutic for Chronic Lymphocytic Leukemia; MOR209/ES414 metastatic castration resistant prostate cancer under collaboration with MorphoSys AG; ES210, a protein therapeutic for inflammation-related indications; 5E3, a monoclonal antibody therapeutic for Alzheimer's disease; and other protein therapeutic product candidates primarily for the treatment of immuno-oncology. The company also provides contract manufacturing services to third-party customers.
****EDGE (T/$21) Developing a sustained-release therapy for limiting brain injury after aneurysms.
***ENDV (T/1.50)... Bioelectronic device, treat acute liver failure (ALF) and other inflammatory conditions in vital organs ... stem cells...
FOLD  AMICUS Therapeutics...biotech rare diseases...
GEMP () clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies.
GNCA (T/$12-40) ....THIS IS A $6 STOCK today...Genocea Biosciences, lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus.  The reason? Genocea announced data from GEN-003 Phase 2b trial in HSV2 demonstrating significant reductions in several measures of genital lesions through 12 months. Nadeau commented, "We are optimistic that GEN-003 will succeed in Phase III, and think that it addresses a significant commercial opportunity. The CDC estimates that 16% of the U.S. population aged >14 has been infected with HSV-2 and that 20-25% of infected people are aware of their status. This implies that GEN-003 could address a market oppy of 8MM - 11MM people in the U.S. alone. Assuming a price of $300 per course, GEN-003's total addressable market would be $2B+."  (07/24) All the 5 analysts polled in the past 12 months rate Genocea stock a Buy. With a return potential of 323%, the stock's consensus target price stands at $24.67.
June 26th FDA...HALO (T/$14-20) ... focused on creating products that help other drugs work better ...The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Recent share dilution...10million shars sold  $12.50 below market price $14.16...

 **HEB biotech for the treatment of viral and immune based chronic disorders...chronic fatigue syndrome=myalic encephalomyelitis   
****KDMN (T/$3.25) Kadmon Holdings markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. It is also developing product candidates in autoimmune and fibrotic diseases, oncology, and genetic diseases. 
MESO ()  specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. 
***MHTX () nanomedicine... *** MNKD commercial-stage diabetes drug and device maker....  
**MRNS 1.13 low (T/$3) biopharm epilepsy and neuropsychiatric disorders... 

 MNTM  Anti-Aging Drug ....SRNE...Sorrento Therapeutics
MTNB (T/$6) ...focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease
NBRV (T/16) ...Developing a novel antibiotic for bacterial pneumonia.
NBY (T/5-6) ...arkets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.

June 19th... NEOS (T/$8H-15) Given FDA approval Juner 19th “With this approval, Neos will be the only company to have both a branded methylphenidate and a branded amphetamine product available in an extended-release orally disintegrating tablet dosage form. We look forward to having Cotempla XR-ODT join our Adzenys XR-ODT®(amphetamine) extended-release orally disintegrating tablets on the market this fall.” Neos Therapeutics is a small-cap pharmaceutical company developing modified-release drugs for the treatment of ADHD and other neurodevelopmental disorders. Currently, the company's only approved branded product is Adzenys XR-ODT, an orally dissolvable tablet (ODT) form of extended-release amphetamine indicated for treatment of attention deficit / hyperactivity disorder (ADHD). Since its launch in May of 2016, sales of Adzenys have been growing well, with a total of 32,296 prescriptions filled between the months of January through March of this year. Monthly prescriptions increased 20% month-over-month during this timeframe, with total Adzenys revenue coming in at $3.1 million. As the company estimates that 54% of kids have difficulty swallowing tablets or capsules, and the total ADHD medication market to be worth $10.4 billion, these sales could have much more room to grow.
NEOT Neothetics...LIPO-202 phase 2 TRIALS. ..specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of localized fat deposits under the chin, or submental fat, as well as for reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. 
*NNVC nano-biopharmaceutical viral infections, shingles cream will be its first drug to start human testing...
NTEC (T/$10) ...Parkinson treatment...
NVAX (T/$1.50) (insider buying 05/11) recombinant nanoparticles vaccines...
 NSTG NanoString Tech (biotech)
wearable electric field device for treating glioblastoma brain cancer...proprietary therapy called TTFields for the treatment of solid tumor cancers. NovoCure believes it will establish TTFields as an important new treatment modality for a variety of solid cancer tumors by increasing survival without increasing side effects when used in combination with other modalities.
NVCR (T/$15) Mesothelioma

07/19  OCRX...Ocera Therapeutics (T/$3-4) (fv $1.69) treatment of hyperammonemia and resultant hepatic encephalopathy
****OCLR (T/$35) OCULAR THERAPEUTIC  JULY 19th FDA should approve Dextenza that treats eye pain after surgery...

OMER... (T/$15H-22H) ...pupil-dilating drug called Omidria, which helps eye surgeons perform cataract removal and lens replacement procedures. While the initial ramp-up was slow, Omidria's sales growth exploded by 212% last year to $41.4 million -- and that could be just the beginning. Since millions of eye surgeries are performed every year, it's possible that Omeros could have a blockbuster on its hands. Omeros is a compound drug called OMS721. This product candidate is being researched as a treatment option for a number of disorders that includes atypical hemolytic-uremic syndrome (aHUS). There is currently only one treatment option for this ultra-rare condition: Alexion Pharmaceuticals' Soliris. Alexion rang up more than $2.8 billion in total Soliris sales last year in part because of its aHUS monopoly. That hints that OMS721 could potentially ring up nine figures in sales on its aHUS opportunity alone.
*****ONCS (T/$3-5)  ...gene therapies...electroporation delivery device, melanoma...
ONTX  1.78 low(T$5.00) (fv $2.39)Onconova targets RAS cellular pathways which have been linked to cancer cells while causing minimal damage to healthy cells. 
*ONVO  ONVO human tissues that could be employed in drug discovery and development,  tissue patches for repair or replacement damaged tissues/organs... tissue assay toxicities would help companies not have to run Phase 1 trials...
OPGN OpGen... VAL-083, an oncology drug for the treatment of refractory glioblastoma multiforme. The company is set to meet with the FDA before the close of the quarter to discuss a Phase 3 study design and has already picked up orphan designation for the drug. On May 5, DelMar reported the closing of a private placement that saw the company pick up gross proceeds of $5.6 million. No company, biotech or otherwise, raises equity-based capital specifically to drive sales efforts if it doesn’t believe there is a thriving market for the product. That OpGen has picked now to raise in order to spend on marketing, and that markets have been responsive to its issue, is indicative of recovery.
****OPK 5.99 low...hemophilia, human growth hormone 
PGNX  (T/$14)  neuroendocrine tumor affects the hormone-producing cells of the body’s neuroendocrine system that comprises of cells which are a combination of hormone-producing endocrine cells and nerve cells. These cells control the flow of air, blood and food through the different body parts. There are no approved therapies available in the U.S. market for the two diseases.
*PRAN biotech development of therapeutic drugs in Australia...
*****PSDV (T/$9)  pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases. 
PIRS (T/$9-10) ...proprietary technology, called Anticalins. They are a mimetic antibody that can be used in many of the same ways antibodies can be used but that are far smaller than antibodies and – as a result – can be applied to a far wider range of indications.
The company’s strategy is simple – create a treatment based on this technology then find a big name to pay for the rights to it. Execution of this strategy has, so far, been flawless. Pieris has deals in place with Roche Holding Ltd. (VTX:ROG), Sanofi SA (ADR) (NYSE:SNY), Servier and, as per our last coverage, AstraZeneca plc (ADR) (NYSE:AZN) ***May 3, 2017 $57 million deal). The combination of these partnerships has the potential to bring more than $4 billion milestone dollars to Pieris and right now the company trades for a market capitalization of less than $200 million.
Well, we’re holding out for some fresh partnership announcements, but that’s not all we’ve got our eye on. There’s a near-term data release that could drive this one into the $7-10 range on its release (conservatively) if it hits press as positive. The drug is called PRS-080 and it’s targeting anemia. Back in February, Pieris struck a deal with Japanese drugmaker ASKA Pharmaceutical Co that saw the latter pick up the rights to the drug in Japan and other Asian regions. Pieris retained the rights in the US and Europe, and the drug advanced into a phase IIa multiple dose study almost immediately after the deal hit press. Data from this trial is expected to be released during the third quarter of this year (latest communication says second half 2017, but trial length/expected completion can be used to narrow this a little).
PSTI (T/$2) ...manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS
******PULM  (this may be a sleeper)  ...Pulmatrix has developed a technology that allows for the encapsulation of an active compound and the delivery of this encapsulated active compound through an inhaler. The technology is called iSperse, and it is designed to overcome some of the drawbacks associated with inhaled active compounds in standard of care treatments. Specifically, and primarily, these drawbacks are rooted in the active compound clumping up at the back of the throat post-inhalation and causing two distinct problems: one, not enough active drug reaching the lungs (and in turn, a lack of efficacy) and two, toxicity-associated side effects caused by the collection of the active compound at the back of the throat. The iSperse technology, for want of a better phrase, lubricates the active compound so it won’t stick together and doesn’t clump, and by proxy, doesn’t get caught in the throat. This allows for a more compact dose in various indications, as less of the active compound needs to be inhaled to have the same amount of it (when compared to standard of care) reaching the lungs. The primary application of this technology right now is in COPD (Cronic Obstructive Pulmonary Disease).
 QBIO story stock glaucoma drug...
RIGL (T/$5) development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc.
ROKA (T/$10)(NEW LOW )Roka Bioscience molecular assay technologies for the detection of foodborne pathogens 
SNGX (T/$4) ... objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax®, in combination with the Company's ricin toxin vaccine, RiVax®, as a medical countermeasure to prevent the effects of ricin exposure. 
****SBOT (T/$4)... Biotech...keyhole limpet hemocyanin (KLH) protein...  POTENTIAL GAME CHANGING TREATMENTS OF SERIOUS DISEASES...When you're developing a vaccine for any indication, you can have a dendritic cell vaccine, you can have a DNA-based vaccine, you can have a KLH-based vaccine or a peptide vaccine, and each one has its own advantages, disadvantages and attributes that you may or may not want as part of the immune response you are targeting. KLH seems to be geared toward generating antibody responses versus T-cell responses. 
 SGYP...(T/$9)Synergy Pharmaceuticals ...therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome  
STML (T/$11)
 TTNP Pharma... treatments for chronic diseases, such as Parkinson's disease. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment.
TXMD (T/$10-20) ...hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
VCEL (T/$6) ... markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
VSTM (T/$6)

Gene Therapy ...
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. According to the Broad Institute, these are the hallmark of a bacterial defense system which forms the basis for the popular CRISPR-Cas9 genome editing technology. In the field of genome engineering, CRISPR is often used loosely to refer to the entire CRISPR-Cas9 system, which can be programmed to target specific stretches of genetic code and to edit DNA at precise locations. The gene editing technology CRISPR/CAS9 is being used to develop a host of new treatments, mostly for genetic diseases. But a team of researchers from the University of Rochester's Center for RNA Biology are investigating whether gene editing can be used for another purpose: to slow the growth of cancer cells.
BTX (T/$6) ...  addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. 
CRSP  (T/$23.50) (fv $9-13CRISPER Therapeutics AG (Buy rating and price target $23.50  by Chardan Capital)  ... focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. Both sides claim victory — angling for millions in potential royalties and licenses — in gene-editing patent dispute 02/16/2017

*EDIT  (T/$33-65???) (on hold until MID 2018) Editas Medicine... Buy rating and $65  price target by Chardan. Biotechnology...the ability to play God...gene therapy.... Editas Medicine is a company that should be on a lot of radars, as they’re working on a revolutionary method of genome editing which could conceivably provide cures for the approximately 6,000 diseases which are caused by genetic mutations in our DNA. Of those, only about 5% currently have approved therapeutic treatments (and those don’t address the root cause, but seek to combat the symptoms). Editas’ genome editing platform CRISPR could instead be used to correct the genetic problem at its source: right in our DNA. A protein-RNA complex can be tailored to either repair or replace damaged genetic sequences, and is then guided to the target spot in the genetic link by a guide RNA. The result is a corrected sequence that could completely cure the issues that were being caused by the defect.There are a couple issues surrounding the company however. Firstly, it could be years before any human trials of the platform are launched. Secondly, Editas Medicine is currently caught in the middle of a heated patent dispute over the CRISPR platform itself, which teams of scientists from Berkeley and the Broad Institute each claim to have the patent rights to. Interestingly, members of both of those teams helped found Editas and still serve as founding scientific advisors for the company.Setting aside the patent dispute, there’s some exciting work being done at Editas that could revolutionize medicine, making this one of the most interesting companies in the world.

*NTLA (T/$19) (fv 7-13) Intellia Therapeutics ...lead target is liver disease ...Intellia Therapeutics Inc is a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product ...headquartered in Cambridge, Massachusetts.

***CLLS (T/$49) (fv$19-50) Cellectis...focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that U.S. patent 8,921,332, which claims the use of chimeric restriction endonucleases for directing chromosomal gene editing in cells by homologous recombination (HR), initially issued on Dec. 30, 2014, has been upheld by the United States Patent and Trademark Office (USPTO) after a reexamination initiated in October 2015. U.S. patent 8,921,332 claims a general method for modifying chromosomal DNA sequences at a genomic site of interest within a cell by using a chimeric restriction endonuclease such as zing finger nucleases, TAL-effector nucleases, Mega-TALs and CRISPR/Cas9. This technique, commonly referred to as gene targeting or targeted insertion, is now frequently used to modify the genome within plants, animals and cell lines.
OPGN () OpGen, Inc. 06/05/2017 announced the results from additional studies supporting the capabilities of its Acuitas Rapid Test and Acuitas Whole Genome Sequence Analysis to accurately predict antibiotic resistance and for infection control
*****QURE  (T/$-13) (fv $7.50-14.50) uniQure... The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

*****ABEO   (T/$14-22)  Abeona gene therapies for life-threatening rare genetic diseases
 Some companies that are related to Abeona Therapeutics include Advaxis (ADXS)NewLink Genetics Corp (NLNK)Compugen (CGEN)Oramed Pharmaceuticals
HTGM (T/$6) instruments molecular profiling applications ...mRNA biomarkers...
**********AST (T/$6-12)Stem Cell regenerative medicine neuro...
ATHX (T/$9) focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions.
**BCLI adult stem cell therapies for neurodegenerative disorders ALS...
***INO (T/$12-13)...Inovio Pharmaceuticals  is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program and Laval University. Inovio Pharmaceuticals (INO +0.4%) and Roche's (OTCQX:RHHBY) Genentech will collaborate on a clinical trial assessing the combination of INO-5401, a T cell-activating immunotherapy, and Tecentriq (atezolizumab) in patients with advanced urothelial carcinoma (bladder cancer). INO ...develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program.
ONCS (T/6)
 (ORMP)Navidea Biopharmaceuticals ***(NAVB),OvaScience (OVAS)NovaBay Pharmaceuticals (NBY)Novogen Limited (NVGN)Prana Biotechnology Limited (PRAN)Caladrius Biosciences (CLBS),  ImmunoCellular Therapeutics Ltd (IMUC)Pharmacyclics (PCYC) and Synageva Biopharma Corp (GEVA).
**ROSG (T/$3.50H)(1:12 REVERSE SPLIT 03/17) Rossetta Genomics... MicroRNAs are a group of genes that are produced using instructions encoded in DNA.
SNY ...the "immortality gene" treats cholestrol in adults hypercholestrolemia
****SGMO  (T/$1717) Sangamo Therapeutics... in May the company announced a new collaboration with Pfizer in hemophilia A. The pair will work together to develop a gene therapy called SB-525, which has received orphan drug designations from the U.S. Food and Drug Administration and the European Medicines Agency. The company's proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. SB-525 is Sangamo’s clinical stage cDNA gene therapy candidate for hemophilia A. = fast-track designation from the FDA will facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill an unmet medical need. SB-525 already enjoys orphan drug status in the U.S. The FDA has cleared an Investigational New Drug application for this program, and a phase I/II clinical trial evaluating SB-525 in adults with hemophilia A is expected to open and begin screening subjects for enrolment by the end of second-quarter 2017. Data from this study are expected in late 2017 or early 2018.

KITE (T-77H) removes a person’s T-cells, engineers them to seek and destroy cancer, multiplies them by the billions then re-introduces them into the body. And although early stage, the results thus far have been extremely positive. KITE is currently conducting a phase I study of their cell therapy in patients with non-Hodgkin lymphoma, has made positive remarks about the progress in press releases and plans to present all of the data at the American Society of Hematology in December— this could potentially be market moving news so traders may look to position themselves accordingly. CAR-T therapy is based on extracting immune system cells out of the patient’s body, fabricating them and infusing them back into the patient’s body to identify and fight the cancer. While the therapy has shown successful results for treating blood cancers, its use has not yielded the desired success for treating solid tumors. Solid tumors are usually an abnormal mass of tissue that may be benign (non-cancerous), or malignant (cancerous). They are classified as sarcomas, carcinomas and lymphomas depending upon the type of cells that form them. The researchers at the University of Pennsylvania's Perelman School of Medicine indicated that CAR-T therapy using double target can be applied for treating a wide range of solid tumors. The combination treatment involved fabricating the T-cells to target a cancer-associated surface protein with shortened carbohydrate molecules. The double-target therapy showed high effectiveness of using new CAR’s in mouse models of pancreatic cancer.
ONCE... BLUE... SMMT... SRPT... Nanopore Technologies (private company)
OPGN () in vitro diagnostic tests designed to identify antimicrobial resistant pathogens, as well as XpressFISH diagnostic test products for the identification of various infectious pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment.
MDXG (T/$20)... MiMedx Group, Inc. develops, patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin, and bone. The company collects the donated human placental tissue and converts into a sterile product through its proprietary PURION process. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. 
PACB  (fv $2.35-4.28) genetic sequencing machine
****AFMD (T/$7) ...its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. 
AGEN (T/$7) Immuno-oncology
ALRN (T/$19-20) Lymphoma...
****APTO (?) Aptose Bioscience CG’806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3demonstrated the superior potency of CG’806, relative to competitive agents, against hematologic malignancy cell lines driven by various WT or mutant forms of FLT3. In addition, once daily oral dosing of CG’806 in a murine model achieved sustained micromolar plasma concentration over a 24hr period, and was accompanied by complete elimination of AML FLT3-ITD tumors in the absence of toxicity. "Given the potency of CG’806 against all of the mutant forms of FLT3 AML and the ability to eradicate AML tumors in murine xenograft models, CG’806 has demonstrated the potential to be superior to other FLT3 inhibitors and is beginning to differentiate itself as a targeted treatment for AML," commented William G. Rice, Ph.D., Chairman and Chief Executive Officer of Aptose. “We believe CG’806 has the potential to become the best-in-class FLT3 inhibitor, and our internal efforts now are focused on delivering CG’806 to AML patients as soon as practicable.”
ARRY (T/$10H-13) Array BioPharma  Many drugs in the pipeline cancer...hepatitis C virus...myeloma and many gene cancer inhibitors...
ATOS biopharmaceutical breast cancer Seattle...
07/31  AVEO (T/$3H)kidney cancer ...European Medicines Agency (EMA) said experts at its Committee for Medicinal Products for Human Use (CHMP) had backed the oral, once-daily drug for marketing approval as a first-line treatment for advanced renal cell carcinoma, or kidney cancer.
***BIOC cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample....
  (T/$3) ...suggests that molecular iodine can specifically inhibit cellullar proliferation and drive cell death in certain breast cancer cell lines without apparent toxicity to normal breast cells. 
*****BPTH (T/$5)
***CALA  (T/$9H)...small molecule drugs directed against tumor metabolism and tumor immunology targets...
CGEN (T/$9-14) ... early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types
****CGIX (T/$6) 
Cancer Genetics... Lung cancer is by far the leading cause of cancer death among both men and women; about 1 out of 4 cancer deaths are from lung cancer. It is the second most common cancer in both men and women (not counting skin cancer). About 14% of all new cancers are lung cancers, with NSCLC accounting for 85% of all lung cancers.[1] It is estimated that in 2017, approximately 222,500 Americans will be diagnosed with lung cancer, and almost 156,000 will die from this disease.[2]

Approved by the FDA on June 22 of 2017, the Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC. Following FDA approval, results from analysis of three of these genes can now be used to identify patients who may be eligible for treatment with one of the following: AstraZeneca's EGFR inhibitor Iressa (gefitinib), Pfizer's ALK and ROS1 inhibitor Xalkori (crizotinib), and the combination therapy of Novartis' MEK inhibitor Mekinist (trametinib) and RAF inhibitor Tafinlar (dabrafenib). With this test, physicians can now match patients to these therapies in days instead of several weeks, which it often takes when screening samples one biomarker at a time.

Recognized as Thermo Fisher's NGS CDx Center of Excellence, CGI is among the first 3 laboratories that will offer the Oncomine Dx Target Test as a service to oncologists. All tests will be run on Thermo Fisher's Ion PGM Dx System, which received FDA 510(k) clearance in parallel for use on formalin-fixed, paraffin-embedded (FFPE) tissue samples. The Oncomine Dx Target Test is a kit and requires as little as 10 nanograms of DNA from FFPE tissues samples - a critical advantage of the test, given the challenge of NSCLC patient samples often being of limited quantity.

CHEK (T/$5-6) medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for precancerous polyps and cancer....
CTMX (T/$25) Preclinical biotech developing tumor-activated cancer immunotherapies.
CYTR ()  The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology
DCTH () ...Delcath Systems, an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. I’d also like to highlight that the clinical potential of Melphalan/HDS in the treatment of ocular melanoma liver metastases was repeatedly supported by compelling clinical data presented and published throughout the past year. Most recently, a single-center retrospective review was published in the American Journal of Clinical Oncology in which the authors found that investigational PHP with Melphalan/HDS offered promising results with a doubling of overall survival (OS) and significantly longer progression-free survival (PFS) and hepatic PFS than other targeted therapies. In addition, an oral presentation at the Regional Cancer Therapies 12th International Symposium reported data from a retrospective, multicenter study demonstrating that 45.7% of patients with ocular melanoma that metastasized to the liver who underwent PHP using investigational Melphalan/HDS experienced a complete or a partial response. That same study further showed that among those who responded to treatment, OS was projected to be more than three years.  The projected 657-day median OS and 1,207-day median OS in patients with a partial or a complete response is very impressive, and we believe speaks to the potential of our system to provide a meaningful and durable response in a disease that has an average survival of only six to eight months.
 *****DMPI  DMPI  (T/$13) DelMar Pharmaceuticals ... focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB). 
****DMTX ($12)
EXAS ...(T/27H) Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer 
****EPZM (T/$20-25) ...Epizyme ... Recent activity appears promising and potentially supportive of accelerated approval, considering there is no established standard of care in the setting. There are 25,000 new cases of follicular lymphoma diagnosed in the U.S. annually, and up to 20% of those patients have the EZH2 mutation. Currently, patients are treated with chemotherapy plus Rituxan. However, most patients end up relapsing, and treatment options when the disease returns are limited. Therefore, the findings in these indications are particularly intriguing.
****FBIO (T-9-11) Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its product includes CNDO-109, a lysate that activates donor natural killer cells for the treatment of cancer-related and other conditions.
******GERN (T/$5) ... lead candidate, imetelstat, appears to have an important advantage over the leading treatment (Jakafi) for a rare form of blood cancer known as myelofibrosis, a disorder marked by overactive blood cell production in bone marrow. In a trial that enrolled 33 myelofibrosis patients, Geron's imetelstat generated a clinical response defined in part by an observed improvement on bone marrow damage among about 21% of patients. Furthermore, 12% experienced a complete remission defined by complete reversal of damage.
GLYC ()...leukemia drug ...rocket because of FDA breakthrough designation
GTHX (T/$30)  engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer. 
 ****GTHX  (T/$30) ... engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.
***IDRA 1.57 low (T/$4-8) cancer rare disease..
*****IMDZ (T/$16-18) ... a prime-boost vaccine approach against NY-ESO-1-expressing tumors, designed to generate an integrated, anti-NY-ESO-1 immune response in vivo via a targeted, specific interaction with dendritic cells, a mechanism of action Immune Design believes differs from traditional cancer vaccines. 
IMGN (T/$11)
**INFI  (T/$2H) treatment of blood cancers...
kmph (T/$8)  ADHD
KPTI (T/$15)  Karyopharm's blood cancer hopeful. Selinexor is a first-in-class oral treatment slated for a large, late-stage combination study with multiple myeloma patients also receiving Velcade and standard chemo. If successful, results from the pivotal trial could eventually support the company's first New Drug Application,
***LBIO  (T/$13-20) (fv $10.71) adoptive cell therapy using tumor-infiltrating lymphocytes  treatment of metastatic melanoma, bladder, lung, breast, and HPV-associated cancers.... (many law suits recently)
MRUS  in Phase 1/2 across three different indications — breast, colorectal and ovarian cancer — and based on data 
NAVB... Lymphoseek, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on activated macrophages.
*OBMP () Bio cancer vaccines...
**OMED  3.20 low (T/$6) (fv $6.68)OncoMed Pharm...anti-cancer stem cell (CSC) and immuno-oncology therapeutics... Lung...Ovarian...Colon... 
OPK (T/$11) Prostate cancer test...Human groth hormone...
PBMD (T/$5-7)
***SNDX (T$/27) ...pipeline of combination therapies in multiple cancer indications. Our lead candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.
THLD biopharmaceutica sm molecule targeting cancers that over express a particular enzyme...
****SNRE  (T/$16) Sorrento Therapeutics... primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. 
TROV (T/$4) Myeliod Leukemia
URGN (T/$28)  Urogen Pharma is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
ZYME (T/19)  Zymeworks lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Pain Relief     The potential market is huge. Over 200 million prescriptions are filled each year for drugs to manage pain outside of the hospital setting. Another 100 million prescriptions are filled annually for managing chronic pain. Over 20 million Americans take prescription drugs for treating uremic pruritus.
07/31 FDA/ 08/03 earnings ACRX²  ACRX  (T/$7)Zalviso Phase 3 trial ..."Since its launch in the first half of 2016, ZALVISO's patient-focused design has garnered positive feedback from patients, who appreciate taking control over their pain, as well as from physicians who are pleased with the product's usability and the desired level of analgesia delivered.
***CARA (T/$20-35) ... Share dilution April... 5 million shares at $18...The company's most advanced product is CR845, an injectable kappa opioid receptor agonist intended for the treatment of acute pain. What makes CR845 special is that unlike traditional pain relief medications (opioids), CR845 targets the "kappa" receptor rather than the "mu" receptor. This means that the drug provides pain relief without many of the side effects associated with traditional opioid therapies such as nausea, vomiting, and respiratory depression. Moreover, because CR845 only acts in the periphery (it cannot enter the brain and spinal cord), the drug is unable to create any of the "euphoric" side effects of traditional opioid pain medications. In layman's terms, this means that CR845 has the potential to provide a non-addictive form of pain relief with fewer of the side effects associated with traditional therapy....its drug development pipeline isn't entirely devoted to cannabinoid or endocannabinoid-mimetic drugs. In fact, Cara Therapeutics, which is entirely clinical-stage at this point, is almost exclusively focused on developing CR845, a kappa opioid receptor agonist (KORA) that has nothing to do with cannabis. Cara's ties to cannabis relate to its preclinical research involving CR701, a cannabinoid receptor agonist that's designed to treat chronic pain. Considering that there were no documented overdose-related deaths from marijuana in 2016, compared to over 20,000 prescription opioid overdose deaths in 2015, there's a clear push to consider CB agonists as a possible solution to chronic pain. In rodent models, CR701 produced "hyperalgesia (sensitization of nerve ending to panful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions." 
  KMPH (T/$8) lead product candidates are an extended release d-threo-methylphenidate product for the treatment of ADHD;  an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. ...also involved in developing a prodrug of hydromorphone for the management of pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. 
****TRVN (T/$9-14) intends to commercialize therapeutics for G protein coupled receptors. The company's central nervous system product pipeline includes Oliceridine, a small molecule G protein biased ligand, which is in Phase III clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment refractory migraine. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase IIb clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. ...
****REPH... (T/$12-21 )Recro Pharma, pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain.
*****PTIE ...(7?) Pain Therapeutics a safer oxycontin = FDA has provided the company with a clear path for Remoxy ER approval if the company completes two studies, one clinical and the other non-clinical. The company expects to successfully complete both clinical studies in 2017 and has the resources to do so. The company ended 2016 with $18.7M in cash and burns $3M/quarter.
  EGLT...   NKTR...  
INSY (T/$16-22)...see marijuana stocks near bottom of this page...the potential applications for dronabinol, including sleep apnea and opioid dependency, could catapult this drug to annual sales in the billions.
**IPCI (T/) pharmaceutical company,...patent on a way to control overdose of prescribed narcotic medications.
KALV (T/$10)  Phase III clinical trial designed to provide rapid sustained relief from pain associated with osteoarthritis...
 RDHL ...STML...blood cancers... AST   spinal cord injuries and cancer ...
 *****FLXN (T/$38) Flexion Therapeutics ...likely approval of the company's first commercial compound by the FDA on the October 6th PDUFA date. It should be approved for the treatment of osterarthritis of the knee and is in trials for two other indications. A recent study showed that Zilretta at a cost of $500 per treatment "had a greater impact on quality-of-life measures than conventional care, diclofenac (NSAID) and HA treatment". This is already a large market and growing as the developed world ages and as society grows more obese.
Zika virus
*BCRX (T/$6H)... XON(T$40)... INO (T/$13) biopharmaceutical, zika virus, Ebola...bladder cancer    SNY...drug manufactures

***Medical/Robotics/Equip The robotic-surgery space is forecast to explode at a compound annual growth rate of more than 22% over the next five years, making it one of the fastest-growing industries in the healthcare sector. Nov. 1,2016
ANGO (T/$21)
APEN (T/$11) ...medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries.
****ATRS (T/$4-5) Antares Pharma ompany develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. 
BLFS (T/$5)
****CHEK (T/$6) Check-Cap Ltd ... development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.  Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally.  This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening... Colorectal cancer is the second leading cause of cancer death in the U.S., with an estimated 135,000 diagnoses and 50,000 deaths in 2017[1].  Despite compelling evidence that screening can detect colorectal cancer and precancerous polyps, nearly one-third of the recommended adult population has never been screened. 
CTSO (T/$7-10-12)  CytoSorbents Corp...critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

ICAD (T/$11)
IVTY (T/$10)
*****MBOT MicroBot Medical... U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key technology patent.  The Patent App. No. 14/348,610, covers a device for the prevention of shunt stenosis.  Micro-robotic technologies... Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH); and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.
**MZOR (T/30H)...Mazor Robotics
******TRXC (T/$2) commercialization of surgical robotic systems company has moved it focus from surgibot to senhance ...
TITXF () robotic surgical system for application in minimally invasive surgery...
STXS robotic systems and instruments for the treatment of abnormal heart rhythms...“The Niobe system is perhaps the most revolutionary invention in the field of cardiac ablation, enabling remote anatomic mapping of electrical currents and eradication of difficult-to-reach arrhythmias with unparalleled safety and pinpoint precision,” said Tung. “Our acquisition of Stereotaxis’ latest generation remote magnetic navigation platform will enhance a highly respected electrophysiology (EP) program that is regarded as a global leader in ablation therapy, research and education, especially in the treatment of ventricular tachycardia (VT), and will greatly improve patients’ lives.”
*EDAP High Intensity Focused Ultrasound (HIFU)(kidney stones, and Urology Devices and Services. AMDA(T/$1.50)
ISRG Intuitive Surgical ...
****ERBA diagnostic test kits automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing...
HTGM (T/$6) instruments molecular profiling applications ...mRNA biomarkers...
NVIV () ...InVivo Therapeutics... focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI.
 NVTR (T/$10H) CyBorg technology...neuroscience...
***MLSS (T/$4)  STA Single Tooth Anesthesia Instrument, a computer-controlled local anesthesia delivery instrument that incorporates the pressure feedback elements of its patented CompuFlo technology, which allows dentists to administer injections into the periodontal ligament space; and CompuDent, a computer-controlled local anesthetic delivery instrument that provides painless injections for various routine dental treatments, including root canals, crowns, fillings, and cleanings. Its products also comprise CompuMed, a computer-controlled injection instrument for use in various applications, such as colorectal surgery, podiatry, dermatology, cosmetic surgery, hair restoration surgery, nasal and sinus surgery, orthopedics, and others. In addition, the company provides The Wand, a hand piece that allows bi-directional rotation during injection, which prevents needle deflection that occurs with a traditional syringe.

NUVA () Minimally invasive spinal surgery MDT... JNJ...PHG...SYK...ZBH
XTNT  (T/$1.50) biomaterial products include OsteoSponge  provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC to fill bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. 

Other Medical
AEZS (T/$4)  07/19 FDA approval for Adult Growth Hormone
***AGRX (T/$10) Women's contrception...weekly patch
ALQA (T/$1.5)
 AMDA (T/$2-5 )biomaterialsValeo silicon nitride spinal fusion devices.(additional shares/dilution Jan 2017 $0.51...
ARDX (T/$12) lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases.
 ARNA (T/$5) ulcerative colitis
ATRA (T/$30)
BIOS (T/$3.50)
BPMX (T/$3) address dermatology and women's health markets. The company offers an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris. The company is also developing BPX02, an injectable product for aesthetic dermatology applications.
CLDX biotech... 
 (T/$5.50) ...operates a health benefits platform in the United States.
***CYTR() CytRx Corp...Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer. According to the American Cancer Society, in 2016 more than 12,300 new cases were diagnosed in the U.S. and approximately 5,000 Americans died from this disease.  In addition, approximately 40,000 new cases and 13,000 deaths in the U.S. and Europe are part of a growing underserved market. Recently, the company announced the U.S. Food and Drug Administration reached an agreement with CytRx on preparations for a New Drug Application submission for aldoxorubicin in soft tissue sarcomas. 2017 American Society of Clinical Oncology (ASCO) Annual Meeting...the data presented at ASCO this year demonstrate that, unlike any other drugs in this class, aldoxorubicin can be dosed continuously with minimal to no cardiotoxicity," commented Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California, and Principal Investigator for the Phase 3 trial.
EXEL Exelixis biotech...
***HLTH (T/$2.50)...outpatient surgery facilities...
MPW (T/$15) Medical Properties RIET
08/08bmo...NEOS  Neos Therapeutics ADHA drugADHA drug approved June 19th 2017...... ...
PSDV (T/$5) chronic eye diseases
KURA  (T/$16) ...protein inhibitors for solid tumors and blood cancers...
SNOA (T/$10) prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue, skincare, and animal healthcare markets in the United States, Latin America, Europe, and rest of the world. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores, and bacteria, such as antibiotic-resistant strains. The company's Microcyn has received fourteen 510(k) clearances for use as a medical device in tissue care management consisting of acute and chronic wounds, and in dermatology applications. 

XTNT (T/$1.50) OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC to fill bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue 
RIGL ... OMER (T/$15H-22H)...FDA Breakout designation for IgA nephrophy

IMGN (T/$6)  
TGEN (T/$6)  Tecogen Inc. designs, manufactures, sells, and services systems that produce electricity, hot water, and air conditioning for commercial installations and buildings, and industrial processes. The company offers cogeneration units that supply electricity and hot water; chillers that provide air-conditioning and hot water; and high-efficiency water heaters. Its products include InVerde, a 100-kilowatt combined heat and power system that primarily provides electricity and hot water; TECOGEN cogeneration system, which produces approximately 500,000 Btu/hr of hot water; TECOCHILL natural gas engine-driven chillers; and Ilios high-efficiency water heaters. The company also provides long-term maintenance contracts, parts sales, and installation services. Tecogen Inc. offers its products and services for hospitals and nursing homes, colleges and universities, health clubs and spas, hotels and motels, office and retail buildings, food and beverage processors, multi-unit residential buildings, laundries, ice rinks, swimming pools, factories, municipal buildings, and military installations. 
AMRS (T/$15)...Amyris, Inc The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. 
***ERII (T/$16-21)energy recovery devices, turbochargers for water desalination/makes equipment for oilfield that makes fracking more efficient .. . 
*AMSC (T/$10-11) now in doubtwind turbine systems... RVLT   (T/$?) sells light emitting diode (LED) lighting solutions...
MNGA (T/$) converts liquid waste into hydrogen based fuels.. *CWST (T/$13H)water treatment... *HCCI (T/16H) oil clean up parts cleaning...
***MXWL  (ultra Capacitors) .. energy storage and power delivery products, ultra-capacitor cells...  
CDTI CDTI  (T/$4) diesel emissions control systems...
***ARTX artx (T/$5)defense and security products sells rechargeable and primary batteries, and smart chargers to the military...
***OPTT (5.3 million share dilution Apr 27)...ocean wave electricity... VTNR  recycle industrial waste... FF biofuel
SPCL (Google finance)...Solaris Power Cells, Inc. is a developmental stage diversified "Green" Energy Storage manufacturer offering residential and commercial users turnkey, renewable energy storage solutions (ESS). Solaris manufactures the Solaris PESA™ "Passive Electron Storage Array"™, for limited use electric vehicles such as golf cars and Mega Energy Storage Systems. (ESS) The Solaris PESA™ is a 100% lead-free, solid-state storage (ESS) solution that makes renewable energy greener and better by allowing applications to utilize more of the energy generated. The Solaris Power Cell™ is capable of providing energy storage to applications normally reliant and equipped with highly toxic lead acid, nickel metal hydride or lithium-ion batteries.
CTRL..(T/$22) home...
ECR (T/$3)
NGPHF  NGPHF Northern Graphite.. *GPHOF .....***FCSMF... *ZENYF ....


Types of Fuel Cells
Ceramic/Solid Oxide Fuel Cells 
BLDP..*PLUG (T/$2h)...**FCEL ...****HYGS .HYGS Hydrogenics
CEFLF ...Ceramic Fuel Cell... CPWHF... NPWZ... HFCO... SSMFF... ITMPF... EVOMF

Solar.... financer and installer...
CAFD (T/$15) November 30, 2015, it owned interests in six utility-scale solar energy projects, two commercial and industrial solar energy projects, and a portfolio of approximately 5,900 residential solar installations with a total capacity of 432 megawatts.
WNDW Solar Window Tech.
RGSE ....02/06 ...$11million dilution and price goes UP... RUN 


***AMSC (T/$7) Wind and electrical grid... utility

Is thorium really that safe?
Thorium of spent rods is still an issue same as with uranium
Uranium Bull Market

NLR...CandleGlance Uranium... URA Global X Uranium ETF ........... 
LTBR Lightbridge Corp... *CCJ(T/$15)  .***URG(T/$1) ...UEC  ...DNN ... URRE...FCUUF Fission Uranium... 

Uranium Energy Corp.(UEC is one of the lowest-cost producers of uranium in the United States. UEC's specialty is in-situ recovery (ISR), the most cost-efficient and environmentally friendly method of extracting uranium.

Energy Storage companies - A new and developing area, so not easy to pick the winners here. Certainly the major battery manufacturers and lithium miners discussed above can benefit. Numerous others to choose from include... 

****ENPH Enphase Energy (T/$4) recent Sept. 23, 2016 secondary stock offering=dilution The company's semiconductor-based microinverter system converts direct current electricity to alternating current (AC) electricity at the individual solar module level. The Enphase AC Battery is a key component of the Enphase Home Energy Solution, the industry's first and only truly integrated offering that combines solar generation, energy control, and storage, and provides homeowners the unique ability to manage their solar and storage together in an integrated fashion. 
Advanced Microgrid Solutions (private ), Fronius (private), Imergy (private), Redflow (ASX:RFX), AES Corp. (NYSE:AES), NEC (OTC:NIPNF), Sharp (OTCPK:SHCAY), Younicos (private, interest held by First Solar), Southern California Edison (SCE), General Electric (NYSE:GE), EnerSys (NYSE:ENS), Johnson Controls (NYSE:JCI), Sony (NYSE:SNE), Sonnen (private) and Origin Energy (NASDAQ:ORG).
Electrovaya (EFL.TO) could well be the little company that could. Developer and manufacturer of portable Lithium-ion battery power solutions for the automotive, power grid, medical and mobile device sectors. The company is based in Mississauga, Ontario, Canada

AES (T/$12) AES Corp... Utility-scale energy storage is expected to surpass 1.6 gigawatts by 2020, edging out the old grid system and making it that much easier to integrate more renewable capacity — once the tech catches up! San Diego Gas & Electric chose a battery design by AES Corp. (NYSE: AES) to begin replacing one of its largest natural gas peaking plants with as much as 300 megawatts of battery storage. The company will also be upgrading the existing plant, but it notes that the end goal is to replace it with renewables later on. Southern California Edison has also contracted Tesla, in a move that should surprise no one by now, to continue building onto its existing 80-megawatt energy storage project in Mira Loma. The system is already online as of this year and can cover peak energy demand for as many as 15,000 California homes. Right now, it’s the biggest lithium battery station operating in the U.S. As it stands, electric cars are still set to be the biggest source of growth in lithium batteries in coming years, but that view could shift if this trend gains traction...
LIT Lithium research 

New Battery better than Lithium...John Goodenough, the 94-year-old father of the lithium-ion battery
ZINC  zinc-based batteries appeal is that they could pack TWICE the power as their lithium-based cousins.
ZZZOF ... GLNCY... HL... HBM... MUX... AG... VEDL (India)
ECSIF eCobalt Solutions... Cobalt metal ... SCTFF ...US Cobalt  a pure play cobalt project that could put the U.S. on the cobalt map in a meaningful way, for the first time in history.
Cobalt metal is in high demand due to growth in the electric vehicle ("EV") market, which uses lithium-ion batteries to power these vehicles (cobalt being a main component). In conjunction, its growing supply deficit is leading the price of the commodity higher. Macquarie Research projected a supply deficit of 885 tonnes in 2018, 3,205 in 2019, and 5,340 in 2020. That comes to a supply deficit increase of 6x in just two years. For large-cap tech companies and automakers looking to produce electric vehicles, the need for cobalt has become increasingly clear given its role in the lithium-ion battery mix. The metal constitutes a little over one-third of a modern lithium-ion battery's composition (and greater than the amount of lithium used itself).
FTSSF ...Fist Colbalt...
How the competition is doing - Larger mining companies also have cobalt operations ongoing, including Freeport-McMoRan (NYSE:FCX) (T/$12-16), Katanga Mining (OTCPK:KATFF), Glencore (GLCNF), Fortune Minerals (OTCQX:FTMDF), Barra Resources (OTC:BRCSF), Tiger Resources (OTC:TRSDF), Lundin Mining (LUNMF), and Cruz Cobalt Corp. (OTCPK:BKTPF).
SMH CandleGlance Semiconductor ...AMD,MVDA,CY,IDTI,IPHI,MPWR,MU,MXIM,TXN,LLTC  .... RESN (T/$8)
SEMI... AIXG (equip Germany) ... ACLS... Semiconductor equip. and materials... TSEM analog intensive mixed-signal semiconductor devices...
CVV (equip) ...materials or coatings for aerospace engine components, medical implants, semiconductors, solar cells, smart glass, carbon nanotubes, nanowires, LEDs, MEMS, and other applications.
LEDS... SemiLEDs Corporation develops, manufactures, and sells light emitting diode (LED) chips and LED components. Its products are used primarily for general lighting applications, including street lights, as well as commercial, industrial, and residential lighting; and specialty industrial applications, such as ultraviolet (UV) applications, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection....Taiwan.
***MU semiconductor systems ..... CY CypressSemi
SINO ...air delivery and frieght services
USDP ...Rail...oil...rail services and oil/gas rail cars... big dividen...If oil continues to fall, it is likely that the return on investment for new pipelines will fall, leading to greater reliance on crude-by-rail. There remains a shortage of pipeline transportation for Canadian tar sands into the U.S. The oil sands are a better opportunity than U.S. shale plays as the asset life is significantly longer (30+ years). The exposure to Canadian oil sands makes it less sensitive to the vagaries of oil prices (see below added discussion about oil sands). The value of rail over pipelines is relatively unknown by most investors. For one, the movement of oil by rail is cheaper than pipelines with lower fixed costs, and it's less capital-intensive. It is also readily scalable. Faster delivery than pipelines by two-thirds (<10 days v. 30 days) with flexibility to choose destination market once the train load is completed.

SEA CandleGlance Shipping TNK,EURN,TGP,NMM,SSW,SFL,TK,TNP, ... SEA vs. VALE 
****GNRT (T/$10) ...potential merger with FRO...= FRO (T/$6) ... TNP (T/$6.50) ...
****SFL (T/$16) 11% dividend... fleet of 16 oil tankers, 22 dry bulk carriers, 20 container vessels, 2 car carriers, 2 jack-up drilling rigs, 2 ultra-deepwater drilling units, 5 offshore supply vessels, 2 chemical tankers, and 2 newbuilding oil pro duct tankers. 
**GMLP...(T/$23)Golar LNG Partners LP owns and operates floating storage regasification units (FSRUs) and liquefied natural gas (LNG) carriers under long-term charters in Brazil, the United Arab Emirates, Indonesia, and Kuwait.
***ASC (T/$10) LNG/LPG carriers 10.68% DIVIDEND(0.71)...**DHT (T/$5H, 6)(0.46bk) oil tankers...
 ***TK () crude oil and LNG has $10.81 cash a share, Dividend% 3.20%
**DSX (T/$3H, 5)  shipping...***DCIX (T/$8) CONTAINER...***DRYS(T$2.53...1.64bk) dry bulk ... **EGLE...(0.04bk) dry bulk...
***ESEA () dry bulk/containers...***GLBS (0.49bk)dry bulk,...**GNK (T/$11H) dry bulk, company has 6.51share in cash... **NMM (T/$2)... dry bulk...  
***SALT dry bulk,
 has $3 a share in cash... SHIP() dry bulk...TOPS (0.34bk) oil tankers...**GASS crude oil and liquefied petroleum gas (LPG) 
ANW shipping, LNG/LPG carriers a marine fuel logistics company markets supplies refined marine fuel and lubricants to vessels in port, at sea, rivers, worldwide ...

Other Stocks 
FPI (T/$10-12) ...Farmland Partners REIT...5% Div. 
FEYE (T/$17)  FireEye, Inc. provides cybersecurity solutions that allow organizations to prepare for, prevent, respond to, and remediate cyber-attacks. 
CELP  (T/$8) oil gas equip. and services...
INFN (T/$12-13)
NSSC (T/$12) security softwar and devices...
ATTO (T/$14)
CPSH ...produces and sells advanced material solutions to transportation, automotive, energy, computing/Internet, telecommunication, aerospace, defense, and oil and gas markets. Its products are used in applications that involve energy use or energy generation. The company primarily offers metal matrix composites that are a combination of metal and ceramic, such as baseplates for various applications, including motor controllers used in electric trains, subway cars, wind turbines, and hybrid and electric vehicles; baseplates and housings for use in radar, satellite, and avionics applications, as well as in modules built with wide band gap semiconductors; and lids and heatspreaders used with integrated circuits for use in Internet switches and routers. It also assembles housings and packages for hybrid circuits. CPS Technologies Corporation primarily sells its products to microelectronics systems companies in the United States
SVU (T/$5-6) wholesale and retail grocer...
***KTOS KTOS..(T/$7H-17) ... provides unmanned aerial, ground, seaborne, command, control, and communications systems.

CCIH  provider of Internet content and application delivery services and cloud in China......
ESES oil/gas service
AMRS ...bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons.
*****LQMT () amorphous metal ( metallic glass/glassy metal) solid metallic material, usually an alloy, disordered atomic-scale structure.
****LKAI () mining/explores for gold, silver, lead, and zinc metals...  NIOBF () niobium/scandium/titanium project located in Nebraska...
PRTS (T/$5)  online after market auto parts
GARWF ()Golden Arrow Resources gold, silver, lead, zinc, and copper. CHNR iron, zinc, and other nonferrous metals in the Peoples Republic of China 
*CRESY agriculture Argentina... INGN oxygen concentrators
**UAMY.. produces and sells antimony, silver, gold, and zeolite products in the United States. The company's Antimony division offers antimony oxide that is primarily used in conjunction with a halogen to form a synergistic flame retardant system for plastics, rubber, fiberglass, textile good...
**AUO liquid crystal displays and other flat panel displays, solar and water re-cycling
JVA. Coffee...   WPX... independent oil and natural gas exploration and production.
(Google)***DMPID ... commercializing anti-cancer therapies ...  
***BTE ...oil Eagle Ford... BRCD Brocade Commucations/Ruckus ...ROX...sells beverage alcohol products in the United States and internationally
BKD  ($T/16H) senior living ...IPAS Telecom Services...  GRMX... IIN...(T/$11) body worn devices...micro-miniature electronics and hearing aids
ZNGA (T/3.50) games... SFE venture capital... GSVC...venture capital pre-IPO... FMCC  Freddie Mac ... FNMA Fannie Mae
NE (T/$7.50) ... SSKN (T/$12?)... VRAY (T/$11)
Larger Cap. Speculation...  
EA (T/$92H-102H) Electronic Arts... NUVA (T/$72H) NuVasive Medical Appliance/equip... ETSY (T/$15) arts/crafts online sellers... UBNT (T/$60-66) Ubiquiti wireless equipment... ALGN (T/$110H) AlignMed. Appliance/equip dental...BOFI (T/$33) bank of internet Bofl Holdings savings and loan... ADRO (T/18) Biotech 
JUNO (T/29) Biotech... INFN (T/$13.50) Commctn Equip...

UA (T/$30) Under Armour apparel clothing... ***SQ (T/$20h)Mobile payment services
WDAY (T/$85H) Workday financial software cloud...   PI (T/$40H) IMPINJ Commmunication equip...

Marijuana Stocks
The HYPE will suck you be careful...

Beginning in 2014, marijuana stocks were in vogue. Investors were scrambling the markets to find almost any stock that promoted themselves as an emerging player in the cannabis industry. The drawback in that investment strategy, however, was that many investors were too preoccupied with finding a company with a catchy name, rather than a company that actually had some substance. While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant's cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions. With that said, if investors had only remained diligent on seeking realistic and lucrative potential through cannabis pharmaceuticals, Vitality Biopharma (OTCQB:VBIO) would not have been overlooked. In fact, VBIO is one of only three cannabinoid related companies that I see as actually being able to produce any meaningful revenue within the next few years. Investors need to separate themselves from the nonsense being promoted by companies that are looking to cultivate and sell the product. Despite what they say, once Big Tobacco decides that it's time to enter the market, these small time entrepreneurial bud houses will be pushed out of business faster than a bee to a beetle. For those investors betting a small fortune on any of these penny stock names, consider saving your money while you still can. The real money will be made in cannabinoid pharmaceuticals (CP)

Marijuana Stock Scams
Inside The Pot Stock Bubble
Cannabis gold rush

The Very First Marijuana Stock ETF Has Lost Investors Money

There's no two ways about it: As an investor, you'd struggle to find an industry with a more appetizing long-term growth rate than legal marijuana.

According to cannabis research firm ArcView, North American legal sales increased by 34%, to $6.9 billion in 2016, albeit black-market sales still totaled $46.4 billion. As more U.S. states push to legalize, and with Canada potentially on the precipice of legalization by 2018, the expectation is more that this $46 billion-plus in illicit sales will shift to the legal and regulated markets in the years to come.

By 2026, investment firm Cowen & Co. anticipates total legal sales could reach $50 billion. If that's the case, we're talking about more than 23% annual growth for a decade. It's these figures that are attracting businesses and investors to marijuana stocks in droves.

HMMJ.TO Medical Marijauna Life Science ETF

Medical Marijuana
ACBFF  Aurora Cannabis another of Canada's medical cannabis producers and retailers.
GBLX () Growblox Sciences is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
On may 23 GBLX announced the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures (“MCCM”). The current US opioid epidemic, along with growing public and government concern regarding opioid abuse, makes new pain treatments a promising field of research and development. Our novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (“THC”), which minimizes their potential for abuse. Pain management represents an estimated health burden of between $560 to $650 billion dollars for chronic pain and between $17 to $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, our novel heart disease formulations address the $316 billion dollar heart therapy market in the US.
GWPH  GW Pharmaceuticals ... developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant 
CARA  () chronic pain ...Cara's ties to cannabis relate to its preclinical research involving CR701, a cannabinoid receptor agonist that's designed to treat chronic pain. Considering that there were no documented overdose-related deaths from marijuana in 2016, compared to over 20,000 prescription opioid overdose deaths in 2015, there's a clear push to consider CB agonists as a possible solution to chronic pain. In rodent models, CR701 produced "hyperalgesia (sensitization of nerve ending to panful stimuli) and allodynia (painful perception of innocuous stimuli) comparable to human conditions." 
****CRBP (T/17-24) Corbus Pharmaceuticals  is considerably more of a wildcard than GW Pharmaceuticals, but if one specific clinical trial goes its way, it could easily leap to $1 billion in annual sales. Corbus' pipeline consists of a solitary drug known as anabasum, which is a synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptors expressed on immune cells and fibroblasts. Its drug is being tested in four indications, but one stands out head and shoulders above the rest: cystic fibrosis (CF). There are few drugs to treat CF, and most that are FDA approved target a very specific mutation, making their impact limited within the CF community. Anabasum is believed to have a global anti-inflammatory effect, meaning it could be taken by most, or all, CF patients.The downside? Even though anabasum hit its primary endpoint of a 75% reduction in the pulmonary exacerbation event rate in phase 2 trials, it didn't provide any improvement in lung function as measured by the forced expiratory volume within the first second (FEV1) test. FEV1 improvement is often seen with FDA approved CF drugs, leaving anabasum's impact on CF somewhat uncertain. (Motley Fool)
ERBB (Google) American Green is heavily banking on the Arizona marijuana market. ERBB signed a Purchase Agreement for a Class A building in Tempe, Arizona that will be a prime location for a Medical Marijuana Dispensary it will lease to one of its license holder clients.
****INSY ...(T-$16-22) Insys ...MEDICAL MARIJUANA, synthesized marijuana cannabidiol...*** 06/16/2017 Insys has been the subject of negative publicity as state and federal investigations continue against six ex-employees regarding the sales and billing practices of the company in the past. The investigations surround the company's drug, Subsys, a fentanyl-based sublingual spray used for the treatment of cancer patients. Insys issued a response to recent media reports by reiterating its commitment towards the highest ethical standards and compliance with all its activities and business practices and complying with governing laws and regulations and cooperating with relevant governmental authorities in ongoing investigations. Management also highlighted that Insys intends to play a meaningful role in providing solutions to address the opioid epidemic by developing innovative products. These potential product solutions include cannabidiol (a novel, non-opioid) for the treatment of opioid dependence, for the treatment of pain and naloxone nasal spray for the treatment of opioid overdose.Recent negative headlines continue to impinge the business risk profile & brand image of the company. Elizabeth Gurrieri, a former manager of reimbursement services for Arizona-based Insys, will plead guilty to one count of wire fraud conspiracy, prosecutors said in a letter filed in Boston federal court. The filing is part of the criminal case against six ex-Insys executives and managers including former Chief Executive Michael Babich, who, prosecutors say, participated in a scheme to bribe doctors to prescribe the drug, Subsys. Gurrieri would become the second former Insys employee nationally to plead guilty in connection with Subsys, an under-the-tongue spray containing fentanyl, a highly addictive and regulated synthetic opioid. 
On the brighter side, FDA approved the final labeling for Syndros (dronabinol oral solution, a pharmaceutical version of THC), which may classify the drug as a Schedule II controlled substance. Insys expects to launch the product in August 2017. Syndros is indicated for the treatment of anorexia associated with weight loss in patients with AIDS and in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros will be a direct competitor to Marinol, a product offered by Abbvie in pill form. Since Syndros is a liquid, it should be easier to swallow and can be administered in prescribed dosages. Dronabinol was approved by the FDA decades ago as a treatment option for cancer patients. Today, the potential applications for dronabinol, including sleep apnea and opioid dependency, could catapult this drug to annual sales in the billions.

MJNA medical marijuana and industrial hemp...Medical Marijuana Inc (OTCMKTS:MJNA), according to company documents, bills itself as an investment holding company that operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high-value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. MJNA saw a gross revenue increase from $1,535,728 in Q1 2016 to $3,612,739 in Q1 2017, a quarter over quarter increase of 135%. Total gross profit increased from $820,446 in Q1 2016 to $2,545,229 in Q1 2017; which is an increase of 210%.
TRPX () ... Therapix Biosciences Ltd is a biopharmaceutical Israeli-based company engaged in identifying and investing in biopharma technologies and developing approved drugs based on cannabinoid molecules. Phase 3 trial Tourette's syndrome, a somewhat bizarre disorder that has become something of a counterculture icon of a disease. Sufferers often have uncontrollable tics, which might include twitching, shouting profanity or other sounds, eye blinking, coughing and throat clearing. It's actually a surprisingly common neurological condition. Studies suggest that the prevalence of Tourette’s in the overall population at any time is 0.1% for impairing cases and 0.6% for all cases.

TWMJF  Canopy Growth Corp.  a producer and retailer of medical cannabis products and oils in Canada

VBIO is intensely focused on treating Narcotic Bowel Syndrome (NBS) and Inflammatory Bowel Disease (IBD). In the case of NBS, it's been reported that up to 81% of opiate users have functional bowel disorders, with more than 58% reporting chronic abdominal pain during an independently conducted study. From this set of patients, over 6% will ultimately develop NBS. The symptoms associated with NBS can be devastating, and it has been reported that the downward spiral related to quality of life issues has been associated with 61% of all drug overdose deaths. In prior, non-related studies, cannabinoids have proven the ability to effectively treat Crohn's disease patients, with over 40% of the patients having had the disease put into remission. These prior results, though unrelated to Vitality Biopharma, do have the potential to open additional regulatory pathways for expedited approval. VBIO product pipeline includes Cannabosides – VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides – VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse, and Huntington’s disease. ??? A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
On March 10 VBIO announced it has obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatment of microbes including Clostridium difficile and other “superbug” pathogens. Utilizing a list of the top drug-resistant pathogens from the United States Centers for Disease Control and Prevention (CDC), Vitality researchers screened for antimicrobial activity in their portfolio of compounds. Vitality Biopharma discovered new antimicrobial activities for cannabinoids, and as a result has filed for patent protection on the use of cannabinoids and cannabinoid prodrugs for the treatment of multiple pathogenic bacterial infections.
*VRTHF...medical marijuana...
***ZYNE () Zynerba Pharmaceuticals are also working on extracting the benefits of cannabis in order to address targeted medical applications.

Other Marijuana
****APHQF  Aphria (NASDAQOTH:APHQF). Aphria has the distinction of being the most prominently profitable marijuana stock, with the company reporting five consecutive quarterly profits.

HEMP  marijuana industries...  Perhaps no other name has personified the pot stock boom and bust more so than Hemp Inc (OTCMKTS:HEMP) CEO Bruce Perlowin. He relished his role as the “King of Pot” and touted his background as a former drug smuggler who served nine years in prison. Well, it seems he never outgrew his old ways as the SEC charged Hemp Inc, Bruce Perlowin, and others with a “long-running and profitable scheme resulted in the sale of hundreds of millions of unregistered and purportedly unrestricted Hemp shares to public investors. The execution of this scheme involved, among other things, purported gifts and consulting agreements that do not appear to have been bona fide and fraudulent statements made to Commission-registered broker-dealers.” June 22, 2016 The sad part is that Hemp was actually making some progress. Last month and after months of waiting, Hemp Inc finally produced its first environmentally friendly product-to-market from the company’s new decortication plant in Spring Hope, North Carolina. This was a pretty big deal for HEMP and its investors as the company has basically bet the ranch on this plant and the state of North Carolina. We told investors back in February that the company was making a comeback and things were finally starting to come together
*** CANN General Cannabis... VNNYF... VPRB... UBQU... MCIG... INSY... CARA ...APHQF... 
 *DIGP cannabis testing; and provides cannabis news with a news/talk radio, ... IGC cannabinoid based biopharmaceutical for end of life supportive care,India...
****INSY ...T-$16-22 MEDICAL MARIJUANA, synthesized marijuana cannabidiol...   *VRTHF...medical marijuana...CBDS...Cannabis Sativa... HMPQ Hemp America...

GRNH GreenGro greenhouse/growing equiptment....

WKHS  (T/$5) Workhorse Group Inc., a technology company, engages in the design, development, manufacture, and sale of electric medium duty trucks and unmanned aerial delivery systems that are integrated with electric vehicles. The company's products are used for commercial step vans in package delivery, product delivery, laundry and uniform service, food service, utility, and special use industries; medium duty buses, including para-transit, shuttle, and school buses; special use vehicles, such as emergency vehicles, wreckers, construction equipment, communications equipment, and military base application vehicles; and recreational vehicles. It also produces chassis with electric, propane, compressed natural gas, and hybrid configurations, as well as gasoline drive systems. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse W-15 light duty platform design is an extension of the E-Gen electric technology used in Workhorse medium-duty delivery trucks, and is believed to be the first plug-in range-extended electric pickup built from the ground up by an original equipment manufacturer (OEM) in America. With an expected 80-mile all-electric range using Panasonic 18650 Li-ion batteries, the battery pack will cover the vast majority of miles driven in a day by fleet operators. If needed, the gasoline generator will initiate after battery power has been depleted, allowing additional range to complete the day's tasks. The W-15 will also feature the ability for utility fleets to power equipment directly from the vehicle's batteries, allowing a crew to complete their duties that require electricity without an external power source. With the goal of being the safest pickup truck in America for fleet operators, the W-15's safety features include an extra large crumple zone and lower center of gravity while still providing ground clearance. The W-15 also offers crash mitigation technologies, including automatic braking and lane centering. Once production commences, the W-15 is anticipated to have a $52,500 MSRP.

After 78 years, the helicopter has been reinvented - SureFly personal helicopter

KNDI...China electric one time this stock traded above $ 2017 there are a ton of law suits after Kandi Technologies ass.

Now what Feb. 14, 2017

With the subsidy-payment drama now behind the company, its focus will be on developing new vehicles that won't rely solely on subsidy payments to be economically viable. Kandi is currently developing those EV products for after 2020, when the subsidy payments end. The company also has its hands full launching two new EV models this year and preparing its car-making joint venture company for its initial public offering.

This will be a pivotal year for Kandi and its investors. But don't expect its stock price to regain its lost value until management proves it can take steps to reduce its reliance on subsidy payments while reigniting its revenue.


Daniel Miller has no position in any stocks mentioned. The Motley Fool
On 22 August 2016. Kandi Technologies Group, Inc. (NASDAQ:KNDI) announced that Kandi Electric Vehicles Group Co., Ltd. (the “JV Company,” a 50/50 joint venture between Kandi and Geely Automobile Holdings Ltd.) has unveiled its new pure electric vehicle (“EV”) model named the “Global Hawk K21.” This new all-electric sedan is equipped with automatic braking technology, a voice control system, a infotainment system, remote software update capabilities, and a fully-integrated electrical control system. Packaged with the ternary battery, the vehicle has a top speed of 100+ km/h and a driving range exceeding 150km on a single full charge. The Global Hawk K21 joins the ranks of mid-tier luxury pure electric vehicles offered by the JV Company.

An Electric Car Vending Machine
Four-Passenger Pure Electric Sedan Vehicle


Marijuana Stocks

Marijuana Stock Scams
Inside The Pot Stock Bubble
Cannabis gold rush
HEMP *HEMP marijuana industries... GRNH GreenGro greenhouse/growing equiptment.... MJNA medical marijuana and industrial hemp...*** CANN General Cannabis... POTN
 *DIGP cannabis testing; and provides cannabis news with a news/talk radio, ... IGC cannabinoid based biopharmaceutical for end of life supportive care,India...
****INSY ...T-$22 MEDICAL MARIJUANA, synthesized marijuana cannabidiol...   *VRTHF...medical marijuana...CBDS...Cannabis Sativa... HMPQ Hemp America...
I long ago concluded that regression to the mean is the most powerful law in financial physics: Periods of above-average performance are inevitably followed by below-average returns, and bad times inevitably set the stage for surprisingly good performance.

These are ten of Bob Farrell’s most famous observations:
1. “Markets tend to return to the mean over time.”  For those of you who’ve taken statistics, you know exactly what this refers to:  stocks often move too far in one direction as euphoria or pessimism clouds people’s thinking.  Investors lose perspective and start believing the little devil on their shoulders.
2. “Excesses in one direction will lead to an opposite excess in the other direction.”  I think of it like bungee jumpers whose cords stretch out and then compress multiple times before they come to rest or achieve equilibrium.
3. “There are no new eras – excesses are never permanent.”  As the latest hot sector climbs higher and higher, you inevitably hear variations of the chorus shouting “it’s different this time”.  Of course, human nature does not change so it never really turns out to be any different.
 4. “Exponential rapidly rising or falling markets usually go further than you think, but they do not correct by going sideways.”  The smart money locks in profits which leads to significant selling and inevitably to a correction.
5.“The public buys the most at the top and the least at the bottom.”  It’s been this way since humans invented commerce.
6.“Fear and greed are stronger than long-term resolve.”  Research in behavioral finance has shown that stock market gains make us exuberant; they enhance well-being and promote optimism which makes investors like to buy.  Losses, on the other hand, bring sadness, disgust, fear and regret.  Fear increases the sense of risk which thereby makes investors shun stocks.
7.“Markets are strongest when they are broad and weakest when they narrow to a handful of equities.”  Think of it as strength in numbers.  Broad breadth (i.e. market participation) and big volume is important.  When wide ranging momentum channels into a small number of stocks, the top is near.
8.“Bear markets have three stages – sharp down move, reflexive rebound and a drawn-out fundamental downtrend.”  
9.“When all the experts and forecasts agree, something else is going to happen.”  Farrell suggests that patient buyers who raise cash in frothy markets and reinvest when sentiment is darkest can profit nicely.
10.“Bull markets are more fun than bear markets.”  It has been my observation that historically the markets have rewarded optimists to a far larger degree than pessimists.  I prefer to play in the bulls’ camp.
Trade well; trade with discipline!-- Gatis Roze

Linda Raschke's 12 Rules for Technical Trading.
1. Buy the first pullback after a new high. Sell the first rally after a new low. 
2. Afternoon strength or weakness should have follow through the next day. 
3. The best trading reversals occur in the morning, not the afternoon. 
4. The larger the market gaps, the greater the odds of continuation and a trend. 
5. The way the market trades around the previous day’s high or low is a good indicator of the market’s technical strength or weakness. 
6. The previous day’s high and low are two very important “pivot” points, for this was the definitive point where buyers or sellers came in the day before. Look for the market to either test and reverse off these points, or push through and show signs of continuation. 
7. The last hour often tells the truth about how strong a trend truly is. “Smart” money shows their hand in the last hour, continuing to mark positions in their favor. As long as a market is having consecutive strong closes, look for up-trend to continue. The up trend is most likely to end when there is a morning rally first, followed by a weak close. 
8. High volume on the close implies continuation the next morning in the direction of the last half-hour. In a strongly trending market, look for resumption of the trend in the last hour. 
9. The first hour’s range establishes the framework for the rest of the trading day
10. A greater percentage of the day’s range occurs in the first hour then was the case in the past, and thus it has become increasingly important to trade aggressively if there are early signs of a strong trend for the day. 
11. There are four basic principles of price behavior which have held up over time. Confidence that a type of price action is a true principle is what allows a trader to develop a systematic approach. The following four principles can be modeled and quantified and hold true for all time frames, all markets. The majority of patterns or systems that have a demonstrable edge are based on one of these four enduring principles of price behavior. Charles Dow was one of the first to touch on them in his writings. 
Principle One: A Trend Has a Higher Probability of Continuation than Reversal 
Principle Two: Momentum Precedes Price 
Principle Three: Trends End in a Climax 
Principle Four: The Market Alternates between Range Expansion and Range Contraction! 
12. In the world of money, which is a world shaped by human behavior, nobody has the foggiest notion of what will happen in the future. Mark that word – Nobody! Thus the successful trader does not base moves on what supposedly will happen but reacts instead to what does happen.

To better understand and appreciate the trading systems seen on this board

Break a bad habit
 "The truth is that trading, both successful and unsuccessful, is more about psychology than tactics." - Jack Schwager

Multicollinearity... Bollinger Bands... CCI...
NOISE...RANDOM...CHAOS...ORDER...STRUCTURE ...if you don't know where you are will you know where you're going?
Structure= creates Order out of CHAOS
Keep Keeping It Simple...Buy low...Sell high...relative to what...? (one day will edit)
Patience...Moving averages...CONFLUENCE..

3day moving average study...Grail QUESTion may cure that gambler in you...with understanding ...gambling/fear gets replaced with confidence and patience...

SLV...3 cross 5 moving average

Adapting Moving Averages to Market Action

Quest of the TREND
Definition for TREND...and...Momentum
Volume speaks VOLUMES...
Momentum volume and momentum Stochastics
Accumulation/Distribution and how to use the Candle Glance Charts
Price gaps occur when the range of a price bar does not include the range of the previous bar. It acts as a reliable level of support and resistance for subsequent price action and should always be monitored.

Does Momentum Investing Work?
Momentum Investing With ETFs
!PMOBUYALL...Percentage of PMO Crossover Buy Signals
Sentiment Extreme Gold Silver

$VIX... "Black Swan"
Hot IPO Pullback
Rules (via 'Hit & Run Trading II'):
#30  Sticky Note 60 minute Sectors kiy 05/18/17 02:02:50 PM
#97   TNTR... Cloud software and flash storage. New stock kiy 07/26/17 10:09:52 PM
#96   HIMX...Having trouble at $9...if you have 30% profit kiy 07/26/17 12:55:43 PM
#95   GNCA (T/$12-40) .... THIS IS A $6 STOCK today ...Cowen kiy 07/25/17 09:54:35 PM
#94   ACRX... It would be nice if price kiy 07/25/17 02:29:11 PM
#93   ZPAS...The Pump and Dumper...taking another DUMP... kiy 07/21/17 03:16:28 PM
#92   INO doing a secondary offering July 25th...offer kiy 07/20/17 02:39:13 PM
#91   ENPH ...I put on 1/3 position on Monday...if kiy 07/19/17 03:06:44 PM
#90   CPE oil and $18 price target is kiy 07/13/17 11:14:11 PM
#89   AST(T/$6-12-) ...another hole-in-the-wall-Joker has a $12 price target kiy 07/12/17 10:23:06 PM
#87   ALIM (T/$3-5)Alimera Sciences... The Company focuses on diseases kiy 07/12/17 11:00:57 AM
#86   USLV...Silver...USLV is UP more than 10% from its kiy 07/12/17 10:19:53 AM
#85   A LINK to news items NOT the many kiy 07/11/17 11:10:55 PM
#83   IOTS (T/$7) ultra low power (flash) memory...trademark resistive kiy 07/08/17 05:26:07 PM
#82   DDDX FLOAT LOCKED ALMOST First Current anyday and Make-a-Bet 07/05/17 01:57:13 PM
#81   DDDX Not going to chase this...but would consider if kiy 07/05/17 01:54:14 PM
#80   DDDX goes current anyday and huge contracts back Make-a-Bet 07/05/17 01:32:49 PM
#79 starting to look more interesting at these lows... kiy 07/05/17 01:31:02 PM
#78   Watching silver as price falls outside the lower kiy 07/05/17 01:21:30 PM
#77   BLPH ... new clinical data from a Phase kiy 06/25/17 12:12:11 PM
#76   AVEO...June 23 (Reuters) - European regulators on Friday kiy 06/25/17 11:54:08 AM
#75   ACRX... Zalviso Phase 3 trial started Sept. 2016...Results kiy 06/25/17 11:35:04 AM
#74   DVAX...Dynavax is nearing a pivotal advisory committee meeting kiy 06/25/17 11:04:30 AM
#73   KTOS has had a nice run...military DRONES... kiy 06/23/17 04:54:50 PM
#72   AUY...looking good...see if any follow through...above the down kiy 06/23/17 04:18:02 PM
#71   BBRY...Market not happy with BBRY's earnings report and guidence... kiy 06/23/17 04:01:43 PM
#70   ZYME (T/19) Zymeworks lead product candidate, ZW25, kiy 06/22/17 09:20:34 PM
#69   URGN (T/$30) Urogen Pharma Ltd, formerly Theracoat Ltd, kiy 06/22/17 09:10:18 PM
#68   GTHX (T/$30) engaged in developing small-molecule therapies kiy 06/22/17 08:59:29 PM
#67   DMPI (T/$13) DelMar Pharmaceuticals ... focuses on the kiy 06/22/17 08:44:49 PM
#66   PSDV (T/$9) pSivida Corp. develops drug delivery kiy 06/22/17 08:30:35 PM
#65   SRNE (T/$16) Sorrento Therapeutics... primary therapeutic focus is kiy 06/22/17 08:14:59 PM
#64   ADXS (T/19-24) Advaxis ...Its LM therapies alter live kiy 06/22/17 07:55:32 PM
#63   ABEO Abeona Therapeutics closed today $ a brokerCROOK kiy 06/22/17 07:00:42 PM
#62   NEOS...60 MINUTE...Don't want to own it below $7.20... kiy 06/22/17 05:02:16 PM
#61   NEOS - Trying to bounce. Still weak. First circlem 06/22/17 01:27:19 PM
#59   AST (T/$6-12) stock is trading at $3.40 and kiy 06/21/17 06:31:13 PM
#58   NEOS... June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, kiy 06/20/17 10:01:15 AM
#57   CHRS (T/$40) Coherus BioSciences, Inc. shares dropped sharply kiy 06/18/17 06:08:28 PM
#56   NEOS...should have some word from the FDA Monday kiy 06/18/17 05:14:08 PM
#55   WKHS (T/$5) Workhorse Group Inc., a technology company, kiy 06/17/17 01:50:44 PM
#54   PULM ( this may be a sleeper ) kiy 06/17/17 12:36:38 PM
#53   Relax, Gold and Silver Investors. So the Fed kiy 06/16/17 01:56:27 PM
#52   ADMP sold 1/4 position 4.50 at 5.75... kiy 06/15/17 03:43:03 PM
#51   added shares at $4.50...nice...full position now... kiy 06/15/17 03:10:52 PM
#50   Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine kiy 06/15/17 02:48:32 PM
#49   ADMP ...TRADING HALT...I just started looking at ADMP kiy 06/15/17 02:35:12 PM
#48   FLXN (T/$38) Flexion Therapeutics ... likely approval of the kiy 06/11/17 04:14:56 PM